3URGXFW'HQRVXPDE$0*
3URWRFRO1XPEHU 
'DWH6HSWHPEHU 3DJHRI
&21),'(17,$/7LWOH$Q2SHQODEHO0XOWLFHQWHU3KDVH6WXG\RI'HQRVXPDE LQ6XEMHFWVZLWK
*LDQW&HOO7XPRURI%RQH
'HQRVXPDE
$PJHQ3URWRFRO1XPEHUGHQRVXPDE
(XGUD&7
&OLQLFDO6WXG\6SRQVRU $PJHQ,QF
2QH$PJHQ&HQWHU'ULYH
7KRXVDQG2DNV&$
.H\866SRQVRU&RQWDFW &OLQLFDO5HVHDU FK6WXG\0DQDJHU
$PJHQ,QF
(PDLO3KRQH
)D[
.H\(86SRQVRU&RQWDFW
&OLQLFDO5HVHDUFK6WXG\
0DQDJHU
$PJHQ6S]RR
(PDLO
3KRQH
)D[
'DWH
$PHQGPHQW
$PHQGPHQW
$PHQGPHQW6XSHUVHGLQJ
$PHQGPHQW
$PHQGPHQW
$PHQGPHQW$PHQGPHQW
$PHQGPHQW
$PHQGPHQW
$PHQGPHQW6XSHUVHGLQJ$SULO
'HFHPEHU
2FWREHU
-DQXDU\
0D\
1RYHPEHU
0D\$XJXVW
0D\
-XO\
6HSWHPEHU
&RQILGHQWLDOLW\1RWLFH
7KLVGRFXPHQWFRQWDLQVFRQILGHQWLD OLQIRUPDWLRQRI$PJHQ,QF 7KLVGRFXPHQWPXVWQRWEH
GLVFORVHGWRDQ\RQHRW KHUWKDQWKHVWXG\V WDIIDQGPHPEHUVRIW KHLQGHSHQGHQWHWKLFV
FRPPLWWHHLQVWLWXWLRQDO UHYLHZERDUG
7KHLQIRUPDWLRQLQWKLVGRFXPHQ WFDQQRWEHXVHGIRUDQ\SXUSRVH RWKHUWKDQWKHHYDOXDWLRQRU
FRQGXFWRIWKHFOLQLFDOLQYHVWLJDWLRQZLWKRXWWKHSULRUZULWWHQ FRQVHQWRI$PJHQ,QF
,I\RXKDYHTXHVWLRQVUHJDUGLQJKR ZWKLVGRFXPHQ WPD\EHXVHGR UVKDUHGFRQWDFW\RXUORFDO
$PJHQ,QFRURQHRIWKHNH\VSRQ VRUFRQWDFWVOLVWHGDERYH
1&71XPEHU
7KLV1&7QXPEHUKDVEHHQDSSOLHGWRWKHGRFXPHQW
IRUSXUSRVHVRISRVWLQJRQFOLQLFDOWULDOVJRY[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2015  Page 2 of 69 
CONFIDENTIAL  Investigator‚Äôs Agreement  
I have read the attached protocol entitled ‚ÄúAn Open-label, Multi -center, Phase 2 Study of 
Denosumab in Subjects with Giant Cell Tumor of Bone‚Äù, dated 15 September  2015, and 
agree to abide by [CONTACT_3769].  
I agree to comply with the International Conference on Harmonisation Tripartite 
Guideline on Good Clinical Practice  and applicable FDA regulations/guidelines set f orth 
in 21 CFR Parts 11, 50, 54, 56, and 312. 
I agree to ensure that Financial Disclosure Statements will be completed by: 
‚Ä¢me (including, if applicable, my spouse [or legal partner] and dependent children)
‚Ä¢my subinvestigators (including, if applicable, their spouses [or legal partners] and
dependent children)
at the start of the study and for up to [ADDRESS_1235942] of the clinical investigation 
without the prior written consent of [COMPANY_010] Inc.  
Signatur
e 
Name [CONTACT_789]  [CONTACT_1782] (DD Month YYYY)  
3URGXFW'HQRVXPDE$0*
3URWRFRO1XPEHU 
'DWH6HSWHPEHU 3DJHRI
&21),'(17,$/3URWRFRO6\QRSVLV
7LWOH$Q2SHQODEHO0XOWLFHQWHU3 KDVH6WXG\RI'HQRVXPDELQ6X EMHFWVZLWK*LDQW&HOO
7XPRURI%RQH
6WXG\3KDVH 
,QGLFDWLRQ 7UHDWPHQWRI*LDQW&HOO7XPRURI%RQH*&7%
3ULPDU\2EMHFWLYH 
7RHYDOXDWHWKHVDIHW\SURILOHR IGHQRVXPDELQVXEMHFWVZLWK*& 7%
6HFRQGDU\2EMHFWLYHV 
xHYDOXDWLRQRIWLPHWRGLVHDVHSUR JUHVVLRQLQVXEMHFWVZLWKXQVD OYDJHDEOH*&7%WUHDWHGZLWK
GHQRVXPDEFRKRUW
xHYDOXDWLRQRIWKHSURSRUWLRQRIV XEMHFWVZKRGRQRWUHTXLUHVXU JHU\LQGHQRVXPDEWUHDWHG
VXEMHFWVZLWKVDOYDJHDEOH*&7%FRKRUW
xWRHYDOXDWHGHQRVXPDESKDUPDFRNL QHWLFV3.LQDGROHVFHQWDQGD GXOWVXEMHFWVZLWK*&7%
3.VXEVHW
+\SRWKHVHV 
,WLVDQWLFLSDWHGWKDWGHQRVXPDE DQLQKLELWRURI5$1./ZLOOE HDZHOOWROHUDWHGWUHDWPHQWIRU
SDWLHQWVZLWKVXUJLFDOO\XQVDOY DJHDEOH*&7%GLVHDVHDQGSDWLHQ WVZLWKVXUJLFDOO\VDOYDJHDEOH
GLVHDVHZKRVHSODQQHGRQVWXG\VXU JHU\LVDVVRFLDWHGZLWKVHYHU HPRUELGLW\
6WXG\'HVLJQ
7KLVLVDSKDVHLQWHUQDWLRQDOP XOWLFHQWHURSHQODEHOVWXG \LQVXEMHFWVZLWK*&7%UHFHLYLQJ
GHQRVXPDEDWDGRVHRIPJVX EFXWDQHRXVO\6&HYHU\ZHHNV 4:ZLWKDORDGLQJGRVH
RIPJ6&RQVWXG \GD\VDQG
7KHUHDUHFRKRUWVLQWKLVVWXG\
x&RKRUW6XEMHFWVZ LWKVXUJLFDOO\XQVDO YDJHDEOHGLVHDVHHJ VDFUDOVSLQDO*&7%RU
PXOWLSOHOHVLRQVLQFOXGLQJSXOPRQDU\PHWDVWDVHV
x&RKRUW6XEMHFWVZLWKVXUJLFDOO\VDOYDJHDEOHGLVHDVHZKRVHS ODQQHGRQVWXG\VXUJHU\LV
DVVRFLDWHGZLWKVHYHUHPRUELGLW \HJMRLQWUHVHFWLRQOLPEDPS XWDWLRQRUKHPLSHOYHFWRP\
x&RKRUW6XEMHFWVZKRDUHFXUU HQWO\SDUWLFLSDWLQJLQ$PJHQV WXG\JLDQWFHOO
WXPRUVWXG\ZKRDUHHOLJLEOHWRHQUROOCCI
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2015  Page 4 of 69 
CONFIDENTIAL    Subjects who are currently receiving denosumab in study 20040215 will receive denosumab at a 
dose of 120 mg dosing according to their current Q4W schedule and will not receive any loading doses (ie, study day 8 and 15).  
For subjects with a complete tumor resection, denosumab treatment continues for 6 doses  after 
pathological confirmation of partial response or complete response.  In all other cases, 
denosumab treatment continues until confirmation of disease progression, investigator‚Äôs 
recommendation of discontinuation, [COMPANY_010]‚Äôs recommendation of discontinuation, the subject‚Äôs decision to discontinue for any reason, or administration of any of the proscribed therapi[INVESTIGATOR_014].  
During the time the study is still open, re- treatment  may be allowed for subjects who 
demonstrated a response to denosumab and are currently not receiving denosumab treatment (eg, in the case of recurrent disease while subject is in the safety follow up phase or subjects that 
have completed the study and have later experienced disease progression).  The re -treatment 
decision including the use of the loading dose and discontinuation of therapy will be handled on a case -by-case basis; prior authorization from [COMPANY_010] is required.  Subjects must meet all 
inclusion/exclusion criteria prior to being considered for re -treatment.  
To evaluate the long -term safety profile of denosumab, data (treatment plus follow -up) will be 
collected for all subjects enrolled through November [ADDRESS_1235943] ( Section 3.4.2 ).  For subjects enrolled after 
November 2012 (PK substudy), data (treatment plus follow -up) will be collected until the end of 
the clinical study ( Section 3.4.2 ).  
Subjects who discontinue(d) investigational product will have an End of Treatment visit approximately [ADDRESS_1235944].  Thereafter, they will complete safety follow -up visits approximately every 6 months (¬± 1 month) for the first year and 
every 12 months (¬± 1 month) thereafter until the end of the clinical study ( Section 3.4.2 ).  During 
the safety follow -up phas e, subjects will be asked about serious adverse events, adverse 
events of interest, and disease treatments and outcomes ( Section 9.2). 
Prior to Amendment 7 IRB/IEC approval, subjects currently in the safety follow -up in study 
20040215 will continue on the safety follow -up in this study for up to 2 years after their end of 
study visit on study 20040215.  The total length of safety follow -up on this  study for patients 
enrolling from the safety follow -up phase of [COMPANY_010] study 20040215 will be 2 years less the time 
spent in safety follow -up on study 20040215.  Upon the approval of Amendment 7, subjects who 
enrolled in 20062004 from the 20040215 study will also follow the 20062004 schedule, and complete the assessments as described in Appendix  A. 
Approximately 50 sites will participate.  
Primary and Sec ondary Endpoints:   
Safety profile of denosumab characterized in terms of the type, frequency, and severity of adverse events and laboratory abnormalities for  each cohort .  
Primary study endpoints:  
Secondary study endpoints
‚Ä¢ time to disease progression for  cohort 1  : 
‚Ä¢ proportion of subjects without any surgery at month 6 for cohort 2  
‚Ä¢ serum denosumab (trough) concentrations  (PK subset)  
Sample Size:    
The number of subjects in this study is determined by [CONTACT_883461].  It  is anticipated that approximately 530 subjects will participate.   Prior to 
Amendment 7, 51 0 subjects were  enrolled.   Following Amendment 7, an additional approximately 
20 subjects ( approximately 10 adolescent s and approximately 10 adult s) will be enrolled to the 
PK substudy.   
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2015  Page 5 of 69 
CONFIDENTIAL    No more than 30 subjects will enroll from the [COMPANY_010] study 20040215.  No adolescents will enroll 
into cohort 3, since all subjects participating in study 20040215 are adults ( ‚â• 18 years of age).  
Summary of Subject Eligibility Criteria:    
‚Ä¢ Pathologically confirmed giant cell tumor of bone within 1 year before study enrollment    Inclusion criteria:  
‚Ä¢ Measurable evidence of active disease within 1 year before study enrollment  
‚Ä¢ Subjects with surgically unsalvageable disease ( eg, sacral, spi[INVESTIGATOR_883431] , or multiple lesions 
including pulmonary metastases) OR s ubjects whose planned surgery includes joint 
resection, limb amputation, hemipelvectomy or surgical procedure resulting in severe 
morbidity   
‚Ä¢ Karnofsky performance status ‚â• 50% (ie, ECOG status 0, 1, or 2) 
‚Ä¢ Adults or skeletally mature adolescents (ie, radiographic evidence of at least 1 mature long 
bone [eg, humerus with closed growth epi[INVESTIGATOR_834984]])  ‚â• 12 years of age  
‚Ä¢ Skeletally mature adolescents must weigh at least 45 kg  
‚Ä¢ Before any study -specific procedure is performed, the appropriate written informed consent 
must be obtained  
Inclusion criteria for 20040215 subjects : 
‚Ä¢ Subjects currently enrolled in study 20040215  
‚Ä¢ Before any study -specific procedure is performed, the appropriate written informed consent 
must be obtained  
‚Ä¢ Currently  receiving other GCTB specific treatment (eg, radiation, chemotherapy, or 
embolization)  Exclusion criteria:  
‚Ä¢ Concurrent bisphosphonate treatment  
‚Ä¢ Known or suspected current diagnosis of underlying malignancy including high- grade 
sarcoma, osteosarcoma, fibrosarcoma, malignant giant cell sarcoma 
‚Ä¢ Known or suspected current diagnosis of non GCTB  giant cell -rich tumors  
‚Ä¢ Known or suspected current diagnosis of brown cell tumor of bone or Paget‚Äôs disease  
‚Ä¢ Known diagnosis of second malignancy within the past 5 years  (subjects with definitively 
treated basal cell carcinoma and cervical carcinoma in situ are permitted) 
‚Ä¢ Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw  
‚Ä¢ Active dental or jaw condition which requires oral surgery, including tooth extraction 
‚Ä¢ Non-healed dental/oral surgery   
‚Ä¢ Planned invasive dental procedure for the course of the study  
‚Ä¢ Subject currently is enrolled in or  has not yet completed at least 30  days since ending other 
investigational device or drug study(s), or subject is receiving other investigational agent(s)  
‚Ä¢ Subject has known sensitivity to any of the products to be administered during dosing  
‚Ä¢ Unstable system ic disease including active infection, uncontrolled hypertension, unstable 
angina, congestive heart failure, or myocardial infarction within 6 months before enrollment  
‚Ä¢ Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after 
the end of treatment  
‚Ä¢ Female subject of child bearing potential is not willing to use a highly effective  method of 
contraception during treatment and for 5 months after the end of treatment  
‚Ä¢ Subject has any kind of disorder that compromises the ability of the subject to give written 
informed consent and/or to comply with study procedures  
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2015  Page 6 of 69 
CONFIDENTIAL    ‚Ä¢ Developed sensitivity to mammalian cell derived drug products during the 20040215 study  Exclusion criteria for 20040215 subjects : 
‚Ä¢ Currently receiving any unapproved investigational product other than denosumab 
‚Ä¢ Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after 
the end of treatment  
‚Ä¢ Female subject of child bearing potential is not willing to use a highly effective method of 
contraception during treatment and for 5 months after the end of treatment  
‚Ä¢ Subject has any kind of disorder that compromises the ability of the subject to give written 
informed consent and/or to comply with study procedures  
Investigational Product Dosage and Administration:    
Denosumab will be supplied in a single use 3.0-mL vial containing 1.7 mL of 70 mg/mL.  Each vial 
contains a sterile, clear, colorless  to slightly yellow , practically free from particles, preservative 
free liquid in open label glass.  Denosumab will be administered as a SC injection.  
All subjects should be adequately supplemented with calcium and vitamin D (at least 
500 mg of calcium and 400 IU of vitamin D),  except in the case of pre- existing hypercalcemia.  
Control Group:    
None 
Procedures:    
Study procedures will only be performed after written independent ethics committee / institutional 
review board (IEC/IRB) approved informed consent is obtained from each subject.   
The site will complete an Inclusion/Exclusion Criteria Worksheet for each subject to be enrolled to 
this study .  Once this worksheet is submitted  to [COMPANY_010] and signed as approved, the site will 
receive a written enrollment confirmation from [COMPANY_010] allowing the specific subject to enroll in the 
study .  The approval process is required for new enrolling subjects  and subjects considered for 
retreatment .  Subjects enrolling from [COMPANY_010] study [ADDRESS_1235945] complete the 
Inclusion/Exclusion Criteria Worksheet, but do not need to complete the approval process .  The 
site must receive the signed enrollment confirmation form back from [COMPANY_010] before dosing may 
begin.  
The following procedures will be performed at screening for all subjects (except 20040215 safety follow -up subjects) enrolled to the study: medical history; Karnofsky performance status; physical 
exam; disease status; pregnancy test for women of childbearing potential; serum collection for anti-denosumab antibody assay (baseline); patient reported outcomes (baseline).  Local 
laboratory values, adverse events, concomitant medications, and treatment procedures will be collected.  Subjects enrolled to the PK substudy will also have serum and urine collection for PK 
and biomarker assessments.   A copy of the standard of care imaging reports obtained within 
[ADDRESS_1235946]‚Äôs 
medical record.  H istopathology reports dated within [ADDRESS_1235947]‚Äôs medical record .  Select 
historical and select on-study imaging performed as standard of care will be required to be sent to 
a central imaging vendor for evaluation of disease response. 
Statistical Considerations:    
The sample size for this study is determined by [CONTACT_883462] .  
It is anticipated that approximately [ADDRESS_1235948]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1235949] from 
the European Medicines Agency that included approximately 507 subjects and a median 
follow up time of 20.8 months . 
Additional  interim analyses may be conducted to monitor the ongoing safety of denosumab or to 
make decisions regarding the use of denosumab in the treatment  of giant cell tumor of bone 
(GCTB). 
Treatment- emergent adverse events, treatment procedures, and anti -denosumab antibodies will 
be summarized for all subjects who receive at least 1 dose of denosumab.  
Sponsor:   [COMPANY_010] Inc.
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2013  Page 8 of 69 
CONFIDENTIAL  Study Design and Treatment Schema 
E
N
R 
O 
L 
L 
M 
E 
N 
T E
N
D 
O 
F 
T 
R
E 
A 
T
M
E
N
TSurgery 
(1)
Cohort 3  
Current 20040215 Subjects (3) 
Denosumab 120 mg SC Q4W if 
receiving Denosumab in [COMPANY_010] 
study 20040215  Complete resection - If 
pathological CR/PR then 
denosumab 120 mg SC 
Q4W for 6 doses (2)Cohort [ADDRESS_1235950] surgery may continue to receive denosumab at a dose of 120 mg SC Q4W if clinical benefit is determined3. Subjects participating in the 20040215 study will enroll and receive denosumab at a dose of 120 mg Q4W (subjects will not receive the day 8 and 15 dose).4. For all subjects, including the PK substudy, data (treatment plus follow-up) will be collected until the end of the clinical study ( Section 3.4.2) which is when
subjects enrolled before Amendment [ADDRESS_1235951] discontinued.  For subjects who discontinue(d)investigational product, safety follow-up visits will be conducted approximately every 6 months (¬± 1 month) after the End of Treatment visit (approximately4 weeks after the last dose of investigational product) for the first year, then every 12 months (¬± 1 month).  The final safety follow-up visit will be conducted at
the time of the end of the cl inical study ( Section 3.4.2) (even if this is not approximately 6 or12 months since the previous follow-up visit).F 
O 
L 
L 
O 
W 
U 
P 
(4) S
C
R 
E 
E 
N 
I 
N 
G 
Study 
Day 1  Study 
Day 8  Study 
Day 15 Week 
5 Week 
9 Week 
13 Week 
17 
+ 
Q4W  Informed 
Consent 
Signed Enroll End of 
Treatment Safety 
Follow up End of 
Study Q4W  Q4W  Q4W  Cohort [ADDRESS_1235952]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 9 of 69 
CONFIDENTIAL  Study Glossary  
Abbreviation/Acronym  Definition  
BPI-SF Brief Pain Inventory ‚Äì Short Form  
CR Complete response  
CTCAE  Common Terminology Criteria for Adverse Events (version 3)  
CT Computed tomography  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic Case R eport Form  
GCTB Giant cell tumor  of bone  
IEC/IRB Independent ethics committee/Institutional review board  
IHC Immunohistochemistry  
IPIM Investigational Product Instruction Manual  
IVRS Interactive Voice Response System  
MRI Magnetic resonance imaging  
ONJ Osteonecrosis of the jaw  
OPG  Osteoprotegerin  
PET Positron emission tomography  
PET/CT  Positron emission tomography/ Computed tomography 
PK Pharmacokinetic (s) 
POR  Proof of Receipt  
PR Partial response  
sCTx Serum C - telopeptide  
SC Subcutaneous  
uNTx Urinary N -telopeptide  
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1235953] recorded measurement prior to the administration of 
denosumab on study day 1  
Disease Status (ie,  physician‚Äôs 
assessment status)  Investigator‚Äôs subjective opi[INVESTIGATOR_121479]‚Äôs health status 
which determines whether subject will enroll, continue treatment, or discontinue the study  
Enrollment  Subject is considered enrolled once the screening procedures have been completed and the eligibility criteria  worksheet is 
completed and signed by [CONTACT_11337]. 
EOS End of Study:  The end of the clinical study for all subjects will 
occur when all subjects enrolled through November 2012 
(before Amendment 7) have completed at least [ADDRESS_1235954].   
Study enrollment (prior to Amendment 7) concluded in November 2012; therefore the final study visi ts will be 
conducted and the study is anticipated to end by [CONTACT_883463] 2017.  
EOT  End of Treatment visit:  the E nd of Treatment visit will occur 
approximately [ADDRESS_1235955] on study day 1, Week 1 
Safety Follow -up Safety Follow Up:   
Subjects who discontinue(d) investigational product will have an 
End of Treatment visit approximately [ADDRESS_1235956].  Thereafter, they will complete safety follow -up visits approximately every 6 months (¬± 1 
month) for the first year and then every 12 months (¬± 1 month) thereafter until the end of the clinical st udy ( Section 
3.4.2).  
Upon the approval of Amendment 7, subjects who enrolled in 
20062004 from the 20040215 study will also follow the 20062004 schedule, and complete the assessments as described in Appendix  A. 
Prior to  Amendment 7 IRB/IEC approval , for subjects enrolling 
from the safety follow -up from study [ADDRESS_1235957]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 11 of 69 
CONFIDENTIAL  TABLE OF CONTENTS  
Protocol Synopsis  ............................................................................................................. 3  
Study Design and Treatment Schema  .............................................................................. 8  
Study Glossary  .................................................................................................................. 9  
1. OBJECTIVES ......................................................................................................... 14
1.1 Primary ....................................................................................................... 14 
1.2 Secondary  .................................................................................................. 14 
1.3 Exploratory  ................................................................................................. 14 
2. BACKGROUND AND RATIONALE  ........................................................................ 14
2.1 Disease  ....................................................................................................... 14 
2.1.1 Clinical Presentation of Giant Cell Tumor of Bone ..................... 14 
2.1.2 Staging and Grading of Giant Cell Tumor of Bone ..................... 16 
2.1.3 Pathophysiology of Giant Cell Tumor of Bone (GCTB)  .............. 16 
2.2
 Denosumab Background ............................................................................ 17 
2.2.1 Clinical Experience With Denosumab in Giant Cell 
Tumor of Bone (GCTB)  .............................................................. 17 
2.2.2 Summary of Effects of OPG -Fc Treatment on Tooth 
Eruption and Long Bone Geometry in Neonate Rats  ................. 18 
2.3 Rationale .................................................................................................... 18 
2.3.1 Selection of Dose ....................................................................... 19 
2.4 Hypo theses  ................................................................................................. 21 
3. EXPERIMENTAL PLAN  ......................................................................................... 21
3.1 Study Design .............................................................................................. 21 
3.2 Number of Centers  ..................................................................................... 22 
3.3 Number of Subjects  .................................................................................... 22 
3.4 Estima ted Study Duration ........................................................................... 23 
3.4.1 Study Duration for Participants ................................................... 23 
3.4.2 End of Study (EOS)  ....................................................................  [ADDRESS_1235958] Dosage, Administration, and Schedule ................. 27 
6.2 Dose Escalation and Stoppi[INVESTIGATOR_1869]  ......................................................... 27 
6.3 Dosage Adjustments  .................................................................................. 28 
6.4 Concomitant Therapy (Calcium and Vitamin D Suppl
ements)  ................... [ADDRESS_1235959]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 12 of 69 
CONFIDENTIAL    6.5 Proscribed Therapy During Study Period ................................................... 28 
7. STUDY PROCEDURES  ......................................................................................... 28 
7.1 Screening/Baseline  ..................................................................................... [ADDRESS_1235960] .......................................................................... 31 
7.7.3 Pharmacokinetic and Serum C -telopeptide (sCTx) 
Assessments (Pharmacokinetic Substudy)  ................................ 31 
7.7.4 Urine Assessments (Pharmacokinetic Substudy)  ....................... 31 
7.7.5 Anti-denosumab Antibody Assay  ................................................ 32 
7.8 Sample Storage and Destruction  ................................................................ 32 
7.9 Patient Reported Outcomes - Brief Pain Inventory - Short Form 
(BPI-SF) ...................................................................................................... 34 
7.10 End of Treatment (EOT) Visit  ..................................................................... [ADDRESS_1235961]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1235962] Treatment Assignments  ................................ 43 
10.5 Interim Analysis and Early Stoppi[INVESTIGATOR_130] ......................................... 43 
10.6 Planned Methods of Analysis  ..................................................................... 43 
10.6.1 General Approach/Considerations  ............................................. [ADDRESS_1235963] Administration ................................ 46 
12. REGULATORY OBLIGATIONS  ............................................................................. 46
12.1 Informed Consent  ....................................................................................... 46 
12.2 Independent Ethics Committee/Institutional Review Board ........................ [ADDRESS_1235964] of Tables 
Table 1.  Estimated 95% Confidence Interval for Example Adverse Event 
Incidence Rates   ....................................................................................... [ADDRESS_1235965] of Appendices 
Appendix  A.  Schedule of Assessments   ......................................................................... 56
Appendix  B.  Adverse Event Severit
y Scoring System   ................................................... 60
Appendix  C.  Pregnancy Notification Worksheet   ............................................................ 61
Appendix  D.  Sample SAE Report Form   ......................................................................... 62
Appendix  E.  Karnofsky Performance Status and Eastern Cooperative 
Oncology Group (ECOG) Performance Status   ........................................ 66
Appendix  F.  Sample Brief Pain Inventor y
 - Short Form (BPI -SF)   .................................. 67
Appendix  G.  Lactation Notification Worksheet   ............................................................... 69
3URGXFW'HQRVXPDE$0*
3URWRFRO1XPEHU'DWH6HSWHPEHU 3DJHRI
&21),'(17,$/ 2%-(&7,9(6
 3ULPDU\7RHYDOXDWHWKHVDIHW\SURILOHRIGHQRVXPDELQVXEMHFWVZLWK*L DQW&HOO7XPRURIERQH
*&7%
 6HFRQGDU\
xHYDOXDWLRQRIWLPHWRGLVHDVHSURJUH VVLRQLQVXEMHFWVZLWKXQVD OYDJHDEOH*&7%
WUHDWHGZLWKGHQRVXPDEFRKRUW
xHYDOXDWLRQRIWKHSURSRUWLRQRIVXEMHFWVZKRGRQRWUHTXLUHVXU JHU\LQGHQRVXPDE
WUHDWHGVXEMHFWVZLWKVDOYDJHDEOH*&7%FRKRUW
xWRHYDOXDWHGHQRVXPDESKDUPDFRNLQHWLFV3.LQDGROHVFHQWDQGD GXOWVXEMHFWVZLWK
*&7%3.VXEVHW
 %$&.*5281'$1'5$7,21$/(
 'LVHDVH
 &OLQLFDO3UHVHQWDWLRQRI*LDQW&HOO7XPRURI%RQH
*LDQWFHOOWXPRURIERQHLVDQXQF RPPRQEHQLJQSULPDU\ERQHWXP RUZLWKORZPDOLJQDQW
SRWHQWLDO,WRFFXUVPRUHFRPPRQO\LQZRPHQWKDQPHQ =KHQJHWDO DQG
WKHUHDUHDSSUR[LPDWHO\QHZO\GLDJQRVHGFDVHVRI*&7%LQWK H8QLWHG6WDWHVHDFK
\HDU
7KHW\SLFDOFOLQLFDOSUHVHQWDWL RQLVDSDLQIXOH[SDQVLYHRVWHRO \WLFOHVLRQXVXDOO\LQWKH
HSLSK\VHVRIORQJERQHVDQGQHDUO\ RIFDVHVRFFXULQWKHU HJLRQRIWKHNQHHCCI
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 15 of 69 
CONFIDENTIAL    (Szendroi  et al, 2003; Szendroi , 2004 ).  Giant cell tumor of bone (GCTB) develops after 
the epi[INVESTIGATOR_883432].  However, cases occur rarely in skeletally mature adolescents (ie, 
adolescents who have closed epi[INVESTIGATOR_728044]) . 
Symptoms that accompany prim ary GCTB  include localized pain, tenderness, and 
swelling and the osteolysis may lead to pathologic fractures, decreased joint motion and impaired function.  Lesions that originate in the spi[INVESTIGATOR_883433].  
Surgery is the definitive therapy for GCTB  and about 80% of primary GCTB  patients 
have lesions amenable to surgical resection.  Although en bloc excisions of the tumor 
may be curative, they also carry significant morbidity (eg, amputation of a limb, joint 
resection) and greatly influence quality of life.  Curettage procedures with and without 
bone graft may allow for complete resection of the tumor and preservation of the limb or 
joint, but the risk for recurrence is greater.  Larger GCTB  lesions may not be amenable 
to curettage resections and may result in severe morbid procedures.  In addition, lesions in bones of the hand and distal radius have the highest rate of metastasis even with 
en bloc excision.  Overall, the risk for recurrence is estimated at 10 to 20 percent after  
en bloc excision and at 40% to 75% ( Malawer et al, 2005) after curettage, albeit a less 
debilitating procedure.  
The GCTB  lesion has a wide transition zone and poorly defined borders.  In order to 
decrease the risk for recurrence with curettage resections, aggressive adjuvant surgical 
procedures are usually necessary.  These procedures are used to remove normal bone 
and ensure a wider surgical margin beyond the transition zone.  Adjuvant procedures such as cryosurgery, phenol instillation, high-speed burr, reconstitution with cement, and/or radiation therapy have been described.  Side effects may include localized bone 
necrosis, increased risk for fracture, and delayed union of bone.  Radiation therapy may 
be used and carries the risk of malignant induction to the bone. 
Prognosis for GCTB  is excellent if it does not recur.  Recurrent GCTB  commonly 
manifests as localized recurrence, however distant recurrence/metastasis may also 
occur.  The definitive therapy for local recurrences is also surgery.  More aggres sive 
surgery for local recurrences carries significant morbidity and patients with local recurrences are at increased risk for subsequent localized and distant recurrences.   
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 16 of 69 
CONFIDENTIAL  Eventually, patients become surgically unsalvageable.  For some patients with pri mary 
spi[INVESTIGATOR_883434], there may be no definitive surgical option.  In these cases, 
treatment options are limited.  Radiation therapy may control local tumor growth; 
however, there is a risk for malignant transformation.  Systemic therapy with 
chem otherapy is of limited value and serial embolization of larger lesions may provide 
symptomatic relief.  
2.1.[ADDRESS_1235966] in GCTB  is not prognostic 
for recurrence or metastasis.  Giant- cell rich osteosarcoma may be difficult to 
differentiate from benign GCTB .  Likewise, the presence of giant cells in osteosarcoma 
is not prognostic for better outcomes.  A grading scale was described; grade I (completely benign), grade II (borderline), and grade III (frankly sarcomatous).  Grade I and II have not been correlated with decreased risk for recurrence or metastasis 
(Malawer  et al, 2005). 
2.1.3 Pathophysiology of Giant Cell Tumor of Bone (GCTB)  
Giant Cell Tumors  of bone (GCTB) are highly vascularized, expansile osteolytic lesions 
with indistinct borders and wide transitional zones.  The histological appearance of giant cell tumors includes three distinct cell types; multinucleated osteoclast-like giant cells, spi[INVESTIGATOR_86853]-shaped osteoblast-like stromal cells and monocytes (likely precursors of the 
giant cells).  Although the name [CONTACT_883488] ‚Äúgiant cells‚Äù are the neoplastic 
component, the true neoplastic component remains unknown and controversial.  The 
similarity in appearance of giant cells to normal osteoclasts suggests that the stromal component (spi[INVESTIGATOR_86853]-shaped cells) may be the true neoplastic component and that the 
giant cells are the reactive component (Morgan et al, 2005; Zheng et al, 2001).    
In archival samples (n = 33) of primary and recurrent GCTB , RANKL was expressed and 
detected by [CONTACT_9064]  (IHC)  and in situ hybridization.  RANKL expression 
was observed in the stromal  component and osteoprotegerin and RANK were expressed 
on the giant cells.  In addition, soluble factors, presumably RANKL, secreted from 
stromal cells of GC TBs are able to induce osteoclastogenesis from peripheral blood 
monocytes (Nishimura et al, 2005).  Although TGF-b1, MCP -1, TNF IL-1, 6, 11, 17, 18, 
MCS -F and PTHrP are expressed in the tumor, none of these factors are known to 
induce osteoclast differentiation.  Endothelial cells of normal vessel did not express RANK or RANKL (Roudier  et al, CTOS  2006). 
 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 17 of 69 
CONFIDENTIAL  2.2 Denosumab Background 
Perturbations in the balance between bone formation and resorption can lead to 
generalized osteoporosis (resulting from estrogen deficiency and aging) or local bone lysis (resulting from rheumatoid arthritis and bone metastases).  RANK -RANK ligand 
(RANKL) system has been identified as an essential mediator of osteoclast formation, 
function, and survival ( Teitelbaum  et al, 2003).  RANKL  binds RANK on osteoclasts or 
osteoclast precursors to stimulate or promote differentiation into osteoclasts and activate mature osteoclasts to resorb bone.  Therefore, RANKL  is a therapeutic target for 
diseases associated with increased bone resorption. 
Denosumab is a fully human monoclonal IgG2 antibody to RANKL  that binds with high 
affinity (Kd 3 x 10
-12 M) and specificity to the soluble and cell membrane- bound forms of 
human RANKL.  Denosumab is highly specific because it binds only to RANKL  and not 
to other members of the tumor necrosis factor (TNF) family, including TNFŒ±, TNF Œ≤, 
TNF-related apoptosis -inducing ligand, or CD40 ligand (Elliott  et al, 2006 ).  Denosumab 
binding prevents the activation of RANK and inhibits the formation, activation, and 
survi val of osteoclasts.  As a consequence, bone resorption and cancer -induced bone 
destruction are reduced.   
Refer to the latest version of the investigator brochure for additional and updated 
information on denosumab background, clinical experience, and safety information. 
2.2.1 Clinical Experience With Denosumab in Giant Cell Tumor  of Bone 
(GCTB)  
The Phase [ADDRESS_1235967] month of treatment.   
The primary endpoint was tumor response, defined as complete or near complete 
elimination of giant cells or in the absence of histology data, a lack of radiologic progression (single largest dimension < 20% increase by [CONTACT_20420] [CT] or magnetic resonance imaging [MRI]). 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 18 of 69 
CONFIDENTIAL  The primary analysis was conducted of 37 subjects (20 female) with a data cut off date 
of 07 April 2 008.  Of these 37 subjects, 35 were evaluable for response to treatment.  
Eighty -six percent (30/35) of subjects had a tumor response:  20 of 20 by [CONTACT_27183], and 
10 of 15 by [CONTACT_268899].  Adverse events (AEs) were reported in [ADDRESS_1235968] diagnosed with 
giant cell sarcoma who developed disease progression (not treatment-related) during the off treatment follow -up period.  No treatment-related serious AEs were reported. 
2.2.2 Summary of Effects of OPG -Fc Treatment on Tooth Eruption and 
Long Bone Geometry in Neonate Rats 
Genetic ablation of RANKL in knockout mice, and lifelong inhibition of RANKL by [CONTACT_883464], was associated with deleterious changes in long bone growth, geometry 
and/or strength ( Ominsky et al, 2009; Li et al, 2000; Kong et al, 1999). RANKL knockout 
mice, but not OPG transgenic rats, also exhibited failure of tooth eruption 
(Kong et al, 1999). The pharmacologic effects of RANKL inhibition on tooth eruption and 
on long bone growth, geometry, and strength were therefore evaluated in several 
nonclinical studies in neonatal rats. RANKL inhibition in neonatal rats via administration 
of OPG -Fc or RANK -Fc resulted in reduced weight gain, growth plate abnormalities, 
reduced bone length, increased bone mass and increased structural bone strength 
parameters. Although material bone strength parameters were on average unchanged, femoral toughness was consistently reduced. Inhibited tooth eruption and impaired root 
developmen t were also observed with doses of OPG -Fc that effected a dramatic 
reduction in bone resorption. These effects were partially reversible upon discontinuation 
of OPG -Fc, however, extrinsic long bone strength was reduced and reduced bone 
length, femur toughness, and abnormal tooth root development persisted.  
Overexpression of OPG in OPG -transgenic (OPG -Tg) rats prenatally through to skeletal 
maturity resulted in a suboptimal long bone phenotype. These data suggest that the use 
of denosumab in the rapi[INVESTIGATOR_883435], decreased bone growth, decreased bone toughness, and impaired dentition.  
2.3 Rationale 
GCTB  is a rare disease characterized clinically by [CONTACT_883465] -nucleated giant cells that are similar to osteoclasts, the cells that 
mediate bone destruction.  The tumor cells express RANKL and its receptor, RANK.  
The RANK/RANKL pathway is an essential mediator of osteoclast function, formation and survival.  Denosumab, a fully human monoclonal antibody of RANKL, inhibits 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1235969]- mediated bone destruction and may provide therapeutic benefit for patients 
with giant cell tumor.   
For subjects with surgically unsalvageable GCTB , current treatment options are limited 
and may include treatments (radiation, embolization, chemotherapy) that lead to 
significant disability, poor quality of life and possibly death.  Bisphosphonates are currently under investigation in this subject population; however, only limited preclinical and clinical data are currently available ( Cheng et al, 2004). 
Study 20040215 was an open-label, phase 2 safety and efficacy study of denosumab in subjects (n = 37 ) with recurrent or unresectable GCTB .  The  primary analysis, 
demonstrated that denosumab has significant biological activity in GCTB  based on 
assessment of histologic or radiologic response.  The safety profile of denosumab in this study appeared to be consistent with that observed in other settings.  
The potential elimination of osteoclasts by [CONTACT_883466], inhibit the progression of GCTB  and potentially 
improve clinical outcomes for these subjects.  
In addition, for patients with surgically salvageable GCTB  that require severe morbid 
procedures, treatment with denosumab may reduce the size of the lesion and improve surgical options to allow limb and joint-sparing procedures . 
There have been rare reported cases  of GCTB  in adolescents.  Giant Cell Tumor of 
Bone (GCTB)  usually occurs  in skeletally mature adolescents after the epi[INVESTIGATOR_883436], and all adolescent subjects enrolled into this study will have radiological 
confirmation of skeletal maturity.  No further long bone growth is anticipated after 
epi[INVESTIGATOR_883437] e closed.  In the adolescent subset, eruption of adult dentition may 
not be complete, but in the majority of cases the non-erupted teeth are likely to be 
limited to non-essential wisdom teeth, which are absent from many adults.  There are 
few treatment options for adolescents with mature skeletons and GCTB .  Based on the 
seriousness of GCTB  and the limited treatment options, [COMPANY_010] believes that this 
protocol, which includes adolescents with mature skeletons and GCTB , presents greater 
than minimal risk, but also presents the prospect of direct benefit to the subject.  
2.3.[ADDRESS_1235970]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 20 of 69 
CONFIDENTIAL    [COMPANY_010] study 20040215.   Subjects enrolling from study 20040215 will receive 
denosumab at a dose of 120 mg dosing according to their current Q4W schedule and 
will not receive any loading doses (ie, study day 8 and 15). 
The selection of the dose and schedule of denosumab was based on safety, 
pharmacokinetic and pharmacodynamic data obtained from the phase 1 and 2 studies 
described above.  Specifically, study 20040113 provided a comprehensive dataset guiding the dose selection for subjects with bone metastases.  All the denosumab arms 
showed biological activity in reducing bone resorption, which was comparable to that 
seen with the IV bisphosphonate arm.  The rate of skeletal -related events in the 
denosumab arms was similar to that observed in the bisphosphonate arm.  Among the denosumab doses and schedules evaluated, the regimen of 120 mg every 4 weeks was 
associated with maximum reduction of the bone turnover marker uNTX by [CONTACT_5875] 13, the 
primary endpoint in the study.  
Unlike the 30 mg every 4-week dosing, the 120 mg every 4- week schedule avoided low 
exposures of denosumab (eg, serum levels below 4000 ng/mL) that could potentially 
translate into reduced efficacy in some subjects based on preliminary population PK/PD 
modeling of the phase 2 data.  Denosumab was found to be safe and well tolerated in all 
study arms.  While no symptomatic hypocalcemia was reported in study 20040113, the 120 mg every 4-week schedule (n = 41) appeared preferable as no grade 2 or higher 
hypocalcemia was recorded as opposed to 5, grade 2 and one, grade 3 hypocalcemia in the denosumab 180 mg every 4- week treatment group (n = 43). 
The subjects on this study have active GCTB  with surgically unsalvageable or large 
GCTB  lesions.  The goal of denosumab treatment is to reduce or halt the growth of the 
GCTB  lesion and prevent further osteolysis.  The pharmacodynamic goal is to quickly 
attain target serum concentrations of denosumab and maintain a constant level of 
maximal s uppression of osteoclast activity and bone resorption. 
Based on the PK model, denosumab [ADDRESS_1235971]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1235972] a similar adverse event profile as adults in this lower  
weight range.   
2.4 Hypotheses 
It is anticipated that denosumab, an inhibitor of RANKL, will be a well -tolerated treatment 
for patients with surgically unsalvageable GCTB  disease, and patients with surgically 
salvageable disease whose planned on-study surgery is associated with severe 
morbidity.  
3. EXPERIMENTAL PLAN  
3.1 Study Design 
This is a  phase 2, international, multi -center, open-label study in subjects with GCTB , 
receiving denosumab at a dose of 120 mg SC Q4W with a loading dose of 120 mg SC 
on study days 8 and 15.   There are 3 cohorts in this study:  
‚Ä¢Cohort #1:  Subjects with surgically unsalvageable disease ( eg, sacral, spi[INVESTIGATOR_883431] ,
or multiple lesions including pulmonary metastases)
‚Ä¢Cohort #2: Subjects with surgically salvageable disease whose planned  on-study
surgery is associated with severe morbi dity (eg, joint resection, limb amputation, or
hemipelvectomy)
‚Ä¢Cohort #3:  Subjects who are currently participating in [COMPANY_010] study 20040215 giant
cell tumor study who are eligible to enroll
Subjects who are currently receiving denosumab in study 20040215 w ill receive 
denosumab at a dose of 120 mg dosing according to their current Q4W schedule and 
will not receive any loading doses (ie, study day 8 and 15). 
For subjects with a complete tumor resection, denosumab treatment continues for 
6 doses after pathological confirmation of partial response (PR) or complete response 
(CR) .  In all other cases, denosumab treatment continues until confirmation of disease 
progression, investigator‚Äôs recommendation of discontinuation, [COMPANY_010]‚Äôs  
recommendation of discontinuation, the subject‚Äôs decision to discontinue for any reason, 
or administration of any of the proscribed therapi[INVESTIGATOR_014]. 
During the time the study is still open,  re-treatment may be allowed for subjects who 
demonstrated a response to denosumab and are currently not receiving denosumab 
treatment (eg, in the case of recurrent disease while subject is in the safety follow up 
phase or subjects that have completed the study and have later experienced disease progression).  The re-treatment decision including the use of the loading dose and 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 22 of 69 
CONFIDENTIAL  discontinuation of therapy will be handled on a case-by -case basis; prior authorization 
from [COMPANY_010] is required.  Subjects must meet all inclusion/exclusion criteria prior to 
being considered for re-treatment.   
To evaluate the long-term safety profile of denosumab, data (treatment plus follow -up) 
will be collected for all subjects enrolled through November [ADDRESS_1235973] (Section 3.4.2).   For 
subjects enrolled after November 2012 (PK substudy), data (treatment plus follow-up) 
will be collected until the end of the clinical study (Section 3.4.2).   
Subjects who discontinue(d) investigational product will have an End of Treatment visit approximately [ADDRESS_1235974].  Thereafter, they will complete safety follow -up visits approximately every 6 months (¬± 1 month) for the 
first year and every 12 months (¬± 1 month) thereafter until the end of the clinical study 
(Section 3.4.2). 
Prior to Amendment 7 IRB/IEC approval, subjects currently in the safety follow-up in 
study [ADDRESS_1235975] within 6 months  of site initiation may be terminated.  
3.3 Number of Subjects 
Participants in this clinical investigation shall be referred to as ‚Äúsubjects‚Äù.  
The sample size for this study is governed by [CONTACT_883462] .  It is anticipated that approximately [ADDRESS_1235976]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 23 of 69 
CONFIDENTIAL  approx imately 20 subjects (approximately 10 adolescents and approximately 10 adults) 
will be enrolled to the PK substudy.  
No more than 30 subjects will enroll from the [COMPANY_010] study 20040215.  No adolescents 
will enroll into cohort 3, since all subjects participating in study 20040215 are adults 
(‚â• 18 years of age). 
3.[ADDRESS_1235977] enrolled through November 2012 (before Amendment 7 ), the total 
duration of a subject‚Äôs participation will be at least [ADDRESS_1235978].  For subjects enrolled 
after November 2012 (PK substudy), data (treatment plus follow -up) will be collected 
until the end of the clinical study (Section 3.4.2).    
The total duration of this study from start of enrollment to end of follow -up for the last 
subject is expected to be approximately 9 years (approximately 4 years of enrollment 
prior to Amendment 7, and approximately 5 years of treatment and follow -up).  
3.4.2 End of Study  (EOS) 
The end of the clinical study  for all subjects  will occur when all subjects enrolled through 
November 2012 (before Amendment 7) have completed at least [ADDRESS_1235979].  Study enrollment (prior to 
Amendment 7) concluded in November 2012; therefore the final study visits will be 
conducted and the study is anticipated to end by  [CONTACT_883467] 2017.  
Subjects enrolled in the PK substudy will complete treatment and/or follow -up at the 
same time as subjects included prior to Amendment 7. 
4. SUBJECT ELIGIBILITY  
Investigators will be expected to maintain a screening log of all potential study 
candidates that includes limited information about the potential candidate (ie, age, sex, 
and race), date, and outcome of the screening process (eg, enrolled into study, reason 
for ineligibility, or refused to participate). 
Before any study -specific procedure, the appropriate written informed consent must be 
obtained (see Section 12.1).  For adolescents , in addition to written informed consent, 
the assent of the adolescent also must be obtained if requested by [CONTACT_38893]/independent ethics committee. 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 24 of 69 
CONFIDENTIAL  4.1 Inclusion Criteria  
Subjects meeting the following criteria are considered eligible for this study.  
4.1.1 Pat hologically confirmed giant cell tumor of bone within 1 year before study 
enrollment 
4.1.2 Measurable evidence of active disease within 1 year before study enrollment 
4.1.3 Subjects with surgically unsalvageable disease ( eg, sacral, spi[INVESTIGATOR_883431] , or 
multiple lesions including pulmonary metastases) OR subjects whose planned 
surgery includes joint resection, limb amputation, hemipelvectomy or surgical 
procedure resulting in severe morbidity  
4.1.4 Karnofsky performance status ‚â•  50% (ie, ECOG status 0, 1, or 2) 
4.1.5 Adults or skeletally mature adolescents (ie, radiographic evidence of at least 1 mature long bone [eg, humerus  with closed growth epi[INVESTIGATOR_834984]]) 
‚â• [ADDRESS_1235980] be obtained 
Inclusion Criteria for 20040215 subjects:  
4.1.[ADDRESS_1235981] be obtained  
4.2 Exclusion Criteria  
4.2.1 Currently receiving other GCTB  specific treatment (eg, radiation, chemotherapy, 
or embolization)  
4.2.2 Concurrent bisphosphonate treatment 
4.2.3 Known or suspected current diagnosis of underlying malignancy including 
high-grade sarcoma, osteosarcoma, fibrosarcoma, malignant giant cell sarcoma 
4.2.4 Known or suspected current diagnosis of non GCTB  giant cell -rich tumors  
4.2.5 Known or suspected current diagnosis of brown cell tumor of bone or Paget‚Äôs 
disease  
4.2.[ADDRESS_1235982] 5 years  (subjects with 
definitively treated basal cell carcinoma and cervical carcinoma in situ are 
permitted) 
4.2.7 Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw  
4.2.8 Active dental or jaw condition which requires oral surgery, including tooth 
extraction 
4.2.9 Non-healed dental/oral surgery 
4.2.[ADDRESS_1235983] 30 days since 
ending other investigational device or drug study(ies), or subject is receiving other investigational agent(s)  
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1235984] to give written informed consent and/or to comply with study procedures  
Exclusion Criteria for 20040215 subjects:  
4.2.[ADDRESS_1235985] to give written informed consent and/or to comply with study procedures  
5. SUBJECT ENROLLMENT  
Before subjects may be entered into the study, [COMPANY_010] requires a copy of the site‚Äôs 
written independent ethics committee/institutional review board (IEC/IRB)  approval of the 
protocol, informed consent form, and all other subject information and/or recruitment 
material, if applicable (see Section 12.3).  
All subjects who enter into the screening period for the study (defined as the point at 
which the subject signs the informed consent) will receive a unique subject identification 
number before any study procedures are performed.  This number will be used to identify the subject throughout the clinical study and must be used on all study documentation related to that subject.  The subject identification number must remain constant throughout the entire clinical study; it must not be changed at the time of 
rescreening or enrollment.  Subjects enrolling from the [ADDRESS_1235986]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1235987] 3 digits will represent a 
protocol identifier (ie, 204) and will be identical for all sites.  The next 3 digits will 
represent the site number (ie, 101, 102, 103, etc.) and will be identical for all subjects at 
a particular site.  The last [ADDRESS_1235988] identification and will be 
assigned in sequential order, per site, as subjects are screened (ie, 00 1, 002, 003, etc.).  
Therefore, the first subject to enter screening at site 101 will receive the number 
204101001; the second subject at this site will receive the number 204101002, etc.  
Once the site deems the subject is eligible for enrollment to the study and all screening procedures have been completed, the Eligibility Criteria Worksheet (found in the Regulatory Binder) and a case history of the subject‚Äôs disease must be completed and 
faxed to the US or European Sponsor Contact (see cover page for contact [CONTACT_3031]) 
as appropriate, for approval before the first dose of investigational product can be 
administered to any  subject.   The approval process is required for new enrolling subjects  
and subjects considered for retreatment .  Subjects enrolling from [COMPANY_010] study 
[ADDRESS_1235989] complete the Inclusion/Exclusion Criteria Worksheet, but do not need to 
complete the approval process.  The case history must include the treatment history , 
including original and translated imaging reports and histopathology reports (specimen 
source must be clearly identified in the report) .  
Those subjects who meet the inclusion/exclusion criteria at the Screening visit and who receive an enrollment confir mation from [COMPANY_010] may be enrolled into the study and 
begin the treatment period.  A  subject is considered enrolled into the study once the 
eligibility criteria worksheet is signed by [CONTACT_11337].  
5.[ADDRESS_1235990] management will be automatically resupplied to the sites through an interactive 
voice response system (IVRS).  
6. TREATMENT PROCEDURES  
Denosumab is considered to be the investigational product in this study; therefore, drug accountability must be obtained on all used and unused denosumab vials.  For further 
details regarding preparation and administration of the investigational product, refer to the Investigational Product Instruction Manual (IPIM), which is a document 
external to this protocol. 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1235991] Dosage, Administration, and Schedule 
Denosumab is to be administered by a licensed healthcare professional at a dose of 
120 mg SC Q4W wit h a loading dose of 120 mg SC on study days 8 and 15.  Subjects 
enrolling from study 20040215 will receive denosumab at a dose of 120 mg dosing 
according to their current Q4W schedule and will not receive any loading doses 
(ie, study day 8 and 15). 
6.2 Dose Escalation and Stoppi[INVESTIGATOR_883438], if the study day s 8 and 15 doses are delayed more than 8 calendar 
days, it will be considered a missed dose and recorded as such on the electronic case 
report form (eC RF).  The next dose is to be given at the next scheduled visit date (based 
on study day 1).  There must be at least 4 days (ie, 96 hours) between the study day s 1, 
8, and 15 doses (ie, ¬±  3 days from the scheduled visit date).  
For Q4W doses, the planned dose may be given up to [ADDRESS_1235992] 21 days between doses.  I f a planned dose 
(eg, week 5, week 9, etc.) is delayed more than 7 calendar days, it will be considered a 
misse d dose and recorded as such on the eCRF .  The next dose is to be given at the 
next scheduled visit date (based on study day 1).  
For subjects with a complete tumor resection, denosumab treatment continues for 6 doses after pathological confirmation of partial response or complete response.  In all 
other cases, denosumab treatment continues until confirmation of disease progression, investigator‚Äôs recommendation of discontinuation, [COMPANY_010]‚Äôs  recommendation of 
discontinuation, the subject‚Äôs decision to discontinue for any reason, or administration of any of the proscribed therapi[INVESTIGATOR_014].  See Section 3.[ADDRESS_1235993] is recommended to  be withheld 30 days prior to 
any elective invasive oral/ dental procedure.  Investigational product administration is 
recommended to be withheld until documented evidence of complete mucosal healing 
following any invasive oral/ dental procedure.  Subjects with osteonecrosis of the jaw (ONJ)  on study may temporarily or permanently 
discontinu e investigational product at investigator discretion.  Re-exposure to 
investigational product may occur if the investigator and sponsor agree subject safety 
will not be compromised. 
The dosing schedule is described by a schema in the protocol synopsis.  
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 28 of 69 
CONFIDENTIAL  6.3 Dosage Adjustments 
There will be no dose adjustments allowed in this study.  
6.4 Concomitant Therapy  (Calcium and Vitamin D Supplements)  
All subjects should be adequately supplemented with calcium and Vitamin D (at 
least 500 mg of calcium and 400 IU of Vitamin D ), except in the case of pre-existing 
hypercalcemia.  Due to differences in regional availability, a dosage form of vitamin D 
that gives an equivalent of at least [ADDRESS_1235994] is on study  (embolization immediately prior to 
planned definitive surgery [ e.g. to improve operative hemostas is] is allowed in 
accordance with local guidelines ).  Use of any unapproved (ie, no marketing 
authorization has been granted) investigational product (other than denosumab) or 
device is not allowed until after all study  assessments are completed. 
Invasive dental procedures should be avoided.  If a subject undergoes an invasive 
dental procedure while on study, a clinical decision to continue the subject on investigational product must be documented in the medical chart. 
7. STUDY PROCEDURES  
It is the responsibility of the investigator to obtain an IEC/IRB -approved, signed, 
informed consent from all subjects before any protocol -related procedures are 
performed.  
Study visits during the treatment period will occur every 4 weeks until the end of 
treatment w ith an additional visit at study days 8 and 15.  For those subjects enrolling 
from the 20040215 study, study visits will continue at every 4 week intervals until the end 
of treatment.  When possible, all assessments/procedures during the treatment phase of 
study should be obtained within 7 calendar days or less of the specified study visit (except during the loading dose period), relative to study day 1.  Every effort should be made to keep subjects on the study schedule as planned from study day  1.   
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 29 of 69 
CONFIDENTIAL  To evaluate the long-term safety profile of denosumab, data (treatment plus follow -up) 
will be collected for all subjects enrolled through November [ADDRESS_1235995] ( Section 3.4.2).  For 
subjects enrolled after November 2012 (PK substudy), data (treatment plus follow-up) 
will be collected until the end of the clinical study (Section 3.4.2).  
Subjects who discontinue(d) investigational product will have an End of Treatment visit approximately [ADDRESS_1235996].  Thereafter, they 
will complete safety follow -up visits approximately every 6 months (¬± 1 month) for the 
first year and every 12 months (¬± 1 month) thereafter until the end of the clinical study 
(Section 3.4.2). 
Prior to Amendment 7 IRB/IEC approval, subjects currently in the safety  follow -up in 
study [ADDRESS_1235997] administration. 
All imaging, histopathology samples and chemistry laboratory samples will be analyzed by [CONTACT_779]'s local laboratory/institution with the exception of antibody samples.  
The schedule of assessments is provided in App endix  A.  
7.1 Screening/Baseline 
Screening assessments conducted as standard of care may be used as screening data 
prior to signing of informed consent if conducted within the required screening period.  
Subjects in Cohort [ADDRESS_1235998] be completed no more than 28 days 
before Study D ay 1 (day of first dose of investigational product) with the following 
exceptions:    
‚Ä¢Histopathology  (reports only):  A copy of all standard of care reports obtained within
[ADDRESS_1235999]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 30 of 69 
CONFIDENTIAL  ‚Ä¢Imaging (eg, PET, CT, PET/CT, MRI or X -ray): A copy of the standard of care reports
obtained within [ADDRESS_1236000] of care will be
required to be sent to a central imaging vendor for evaluation of disease response.
‚Ä¢A negative pregnancy test, for women with reproductive potential, must be
documented no more than [ADDRESS_1236001] dose of denosumab (Study Day  1).  If a
pregnancy test result will be more than [ADDRESS_1236002] be repeated and documented in the eCRF.
‚Ä¢Informed consent may be obtained more than [ADDRESS_1236003]‚Äôs medical history will be obtained ‚â§ [ADDRESS_1236004] be 
documented on the eCRF  (and in the source documents).  Any illness or medical 
condit ion that is ongoing at the time of the subject‚Äôs first dose of study drug 
should be noted.  Worsening of a pre-existing condition should be reported as an 
adverse event.   
7.[ADDRESS_1236005]‚Äôs primary and metastatic giant cell tumor  of bone will be 
collected.  
7.4 Physical Examination 
Each physical examination visit will include assessment of Karnofsky  performance 
status, disease status , vital signs  (screening only) , height (screening only) , and weight 
(screening only).  Refer to Appendix E for Karnofsky performance status criteria.  
7.4.1 Oral Examination 
A visual examination of the oral cavity (oral examination), including teeth, mucosa, and 
jaws, will be conducted by [CONTACT_093], or designated licensed healthcare professional, at screening (for newly enrolled subjects), to establish baseline oral health 
conditions, and approximately at least 24 weeks thereafter (approximately every 
6 months) to identify and document any new abnormalities or changes in pre-existing 
conditions.  Routine oral examinations should be conducted as part of standard subject 
management. 
Appropriate preventive dentistry should be considered prior to treatment with 
denosumab. 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 31 of 69 
CONFIDENTIAL  If any new abnormalities or changes in pre-existing conditions are identified, additional 
information may be requested.  
7.5 Imaging 
A copy of imaging reports (eg, PET, CT, PET/CT, MRI, or X -ray) performed as standard 
of care must be attached to the subject‚Äôs medical record.  Select on-study imaging 
performed as standard of care will be required to be sent to a central imaging vendor for evaluation of disease response.     
7.[ADDRESS_1236006]‚Äôs medical record, i ncluding the surgical report of the GCTB  target lesion 
resection.  The histopathology samples and reports may be requested either during the 
study or at end of study  for evaluation of histopathological response to treatment . 
7.[ADDRESS_1236007] ry 
At a minimum, calcium, albumin, magnesium, phosphorus, and creatinine will be 
collected and analyzed at the site‚Äôs local laboratory.  No lab supplies will be provided to 
sites for these tests.  
7.7.[ADDRESS_1236008]  
Urine/serum pregnancy labs will be collected and analyzed at the site‚Äôs local laboratory.  No lab supplies will be provided to sites for these tests.  
7.7.3 Pharmacokinetic and Serum C -telopeptide (sCTx) Assessments 
(Pharmacokinetic Substudy)   
Serum s amples for serum denosumab concentration levels and sCTx will be obtained on 
a 
subset of approximately 20 subjects
Appendix  A (approximately 10 adolescent and 10 adult 
subjects) at baseline (prior to administration of investigational product on study day 1)  
and on study as outlined in the schedule of assessments  ( ).  [COMPANY_010] Inc or its 
designee will be responsible for analyzing these samples. 
7.7.4 Urine Assessments (Pharmacokinetic Substudy)  
All urine samples will be collected prior to investigational product administration. Urine 
samples will be collected for urinary N-telopeptide (uNTx).  Urine analytes will include 
creatinine and raw N -telopeptide (NTx).  [COMPANY_010] Inc or its designee will perform these 
assays and will measure urine creatinine. 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 32 of 69 
CONFIDENTIAL  The uNTx will be corrected for urine creatinine by [CONTACT_57148] a ratio.  Using the uNTx as 
reported in units of nM and urine creatinine in units of mg/dL, the creatinine 
measurement will be multiplied by 0.0884, and used to generate the corrected ratio.  The 
resulting equation will be:  uNTx/Cr (nM BCE/mM) = uNTx/(Cr*0.0884). 
Urine will be obtained on a subset of approximately 20 subjects (approximately 
10 adolescent and 10 adult subjects) at baseline (prior to administration of 
investigational product on study day 1)  and on study as outlined in the schedule of 
assessments  (Appendix  A).  
Urine collection instructions 
A urine sample will be collected from subjects after the first void and preferably in the 
morning.  It is recommended that urine samples be collected in the clinic, if feasible.  If 
the subject is to collect the urine sample at home, he/she will need to be provided with 
containers for sample collection and for transporting the sample to the site on the day of collection.  Subject instructions will be provided on how and when to collect the sample, 
recording the time of collection, and storing the sample (refrigerated) until it is brought to the study site for processing.  
7.7.5 Anti-denosumab Antibody Assay 
Serum for anti -denosumab antibody assay will be collected at baseline and as outlined 
on the schedule of assessments (Appendix  A).  
Prior to Amendment 7 IRB/IEC approval, for subjects who were in the safety  follow -up of 
study 20040215 and are enrolling in this study, serum samples for anti -denosumab 
antibody assay will  be collected approximately every 6 months for up to 24 months after 
the end of study visit in the 20040215 study.  Upon the approval of Amendment 7, 
subjects who enrolled in 20062004 from the 20040215 study will also follow the 
20062004 schedule, and complete the assessments as described in Appendix  A. 
[COMPANY_010] Inc., or its designee, will be responsible for analyzing serum samples for the assessment of anti -denosumab antibodies.  [COMPANY_010] Biological Sample Management 
(BSM) will provide a study manual that outlines handling, labeling, and shippi[INVESTIGATOR_883439].
  These samples may also be used for future biomarker 
development testing.  
7.8 Sample Storage and Destruction 
Any serum or urine samples collected according to the s chedule of a ssessments 
(Appendix  A) can be analyzed for any of the tests  outlined in  the protocol and for any 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236009]‚Äôs identification number for the study.  Results are stored in a secure 
database to ensure confidentiality.   
If informed consent is provided by [CONTACT_423], [COMPANY_010] can do additional testing on 
remaining samples (ie, residual and back -up) to investigate and better understand Giant 
Cell Tumor of Bone, the dose response and/or prediction of response to denosumab,  
characterize antibody response, and characterize aspects of the molecule (eg, mechanism of action/target, metabolites).  Results from this analysis are to be 
documented and maintained, but are not necessarily reported as part of this study.  Samples can be retained for up to [ADDRESS_1236010]‚Äôs medical record and are not to be made available to the subject, members of the family, the personal physician, or other 
third parties, except as specified in the informed consent.  
The subject retains the right to request that the sample material be destroyed by 
[CONTACT_21947].  Following the request from the subject, the investigator is to 
provide the sponsor with the required study and subject number so that any remaining serum or urine samples and any other components from the cells can be located and 
destroyed.  Samples will be destroyed once all protocol -defined procedures are 
completed.  However, information collected from samples prior to the request for destruction, will be retained by [CONTACT_11337]. 
The sponsor is the exclusive owner of any data, discoveries, or derivative materials from 
the sample materials and is responsible for the destruction of the sample(s) at the request of the subject through the Investigator, at the end of the storage period, or as 
appropriate (eg, the scientific rationale for experimentation with a certain sample type no 
longer justifies keepi[INVESTIGATOR_21878]).  If a commercial product is developed from this research project, the sponsor owns the commercial product.  The subject has no 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236011] and has no commercial rights to the data, information, 
discoveries, or derivative materials gained or produced from the sample. 
7.9 Patient Reported Outcomes - Brief Pain Inventory  - Short  Form 
(BPI-SF) 
The BPI-SF is a patient completed questionnaire that has been shown to be a valid 
measure of pain in cancer ( Cleeland CS, 1991).  It captures information on the intensity 
of pain (pain severity) as well as the degree to which pain interferes with function (pain interference).  The BPI-SF will be collected prior to each administration of investigational 
produc t.  
7.10 End of Treatment (EOT ) Visit  
Each subject will have an End of Treatment visit approximately [ADDRESS_1236012].  Study procedures are listed in Appendix  A. 
7.11 Safety Follow -up Phase 
Subjects who discontinue(d) investigational product will have an End of Treatment visit approximately [ADDRESS_1236013].  Thereafter, they 
will complete safety follow -up visits approximately every 6 months (¬± 1 month) for the 
first year and then every 12 months (¬± 1 month) thereafter until the end of the clinical 
study ( Section 3.4.2).   During the safety follow -up phase, subjects will be asked 
about serious adverse events, adverse events of interest, and disease treatments 
and outcomes (Section 9.2).  
Upon the approval of Amendment 7, subjects who enrolled in 20062004 from the 
20040215 study will also follow the 20062004 schedule, and complete the assessments 
as described in Appendix  A. 
Prior to  Amendment 7 IRB/IEC approval , for subjects who were in the safety  follow -up 
on study [ADDRESS_1236014] be 
conducted in the clinic.  Thereafter, subjects may be contact[CONTACT_883468] (eg, telephone) to complete the assessments.  
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236015]:  
‚Ä¢ONJ
‚Ä¢Malignancy, including malignancy in GCTB
‚Ä¢Atypi[INVESTIGATOR_883440], specific 
additional information will be requested/collected as necessary according to each 
type of event.  The additional information will include, but is not limited to:  
‚Ä¢ONJ:  dental records; information will be sent for adjudication by
[CONTACT_155975] (see Section 9.4.1)
‚Ä¢Malignancy (including malignancy in GCTB):  pathology reports
‚Ä¢Atypi[INVESTIGATOR_883441] f racture:  x-ray or other imaging; medical/surgical
records.  Information will be sent for adjudication by [CONTACT_883469] (see Section 9.4.1).
If the subject has experienced any serious adverse event ( Section 9.1.2), 
information is to be collected and reported (see Section 9.3). 
If the subject has been receiving treatment with commercial denosumab (XGEVA), or any other [COMPANY_010] product as standard of care for GCTB or any other condition, Adverse Drug Reactions related to that product will be collected. 
8. REMOVAL AND REPLACEMENT OF SUBJECTS  
8.[ADDRESS_1236016]‚Äôs health.   
Withdrawal of partial consent means that the subject does not wish to take investigational product any longer but is still willing to collaborate in providing further data by [CONTACT_178931] ( eg, participate in all subsequent study visits or procedures).  
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236017] for other reasons ( eg, investigator or sponsor concern) should continue the 
schedule of study observations.   
Reasons for removal from investigational product or observation might include: 
‚Ä¢withdrawal of consent
‚Ä¢administrative decision by [CONTACT_883470]
‚Ä¢pregnancy (report on Pregnancy Notification Worksheet, see  Appendix  C)
‚Ä¢ineligibility
‚Ä¢significant protocol deviation
‚Ä¢subject noncompliance
‚Ä¢adverse event
‚Ä¢disease progression
‚Ä¢administration of bisphosphonates  or other proscribed therapi[INVESTIGATOR_014]
8.2 Replacement of Subjects 
No subjects will be replaced. 
9. SAFETY DATA COLLECTION, RECORDING, AND REPORTING  
9.1 Definitions 
9.1.1 Adverse Events 
An adverse event is defined in the International Conference on Harmonisation (ICH) 
Guideline for Good Clinical Practice as ‚Äúany untoward medical occurrence in a patient or 
clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.‚Äù (ICH E6:1.2)  
This definition of adverse events is broadened in this study to include any such occurrence (eg, sign, symptom, or diagnosis) or worsening of a pre-existing medical condition from the time that a subject has signed informed consent to the time of enrollment to or initiation of investigational product.  
This definition of adverse events also includes worsening of a pre-existing medical condition.  Worsening indicates that the pre-existing medical condition (eg, cancer, diabetes, migraine headaches, gout) has  increased in severity, frequency, or duration of 
the condition or an association with significantly worse outcomes. 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 37 of 69 
CONFIDENTIAL  Interventions for pretreatment conditions (eg, elective cosmetic surgery) or medical 
procedures that were planned before study enrollment are not considered adverse events. 
Pregnancy is not considered an adverse event (see Appendix  C for reporting any 
pregnancy). 
The investigator is responsible for reviewing laboratory test results and determining 
whether an abnormal value in an individual study subject represents a change from 
values before the study.  In general, abnormal laboratory findings without clinical 
significance (based on the investigator's judgment) should not be recorded as adverse events; however, laboratory value changes requiring therapy or adjustment in pr ior 
therapy are considered adverse events.  
9.1.2 Serious Adverse Events 
A serious adverse event (SAE) is defined as an adverse event that meets at least 1 of 
the following serious criteria: 
‚Ä¢is fatal
‚Ä¢is life threatening (places the subject at immediate risk of de ath)
‚Ä¢requires in-patient hospi[INVESTIGATOR_1081]
‚Ä¢results in persistent or significant disability/incapacity
‚Ä¢is a congenital anomaly/birth defect
‚Ä¢other significant medical hazard
A hospi[INVESTIGATOR_37349] ‚Äúserious‚Äù is any inpatient hospi[INVESTIGATOR_256170] a minimum of an overnight stay in a health care facility excluding 
hospi[INVESTIGATOR_883442] -specified procedures ( eg, to perform resection 
on affected limb/region with giant cell tumor) or blood product transfusions, if being administered for cancer -related treatment.  However, prolongation of hospi[INVESTIGATOR_883443]-admission after the subject has been discharged would be considered a Serious Adverse Event.  Elective hospi[INVESTIGATOR_883444].  
Any adverse event that does not meet one of the definitions of serious (eg, emergency room visit, outpatient surgery, or requires urgent investigation) may be considered by [CONTACT_883471] ‚Äúother significant medical hazard‚Äù criterion for classification as a 
serious adverse event.  Examples include allergic bronchospasm, convulsions, and blood dyscrasias.  
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 38 of 69 
CONFIDENTIAL  9.2 Reporting Procedures for All Adverse Events 
The investigator is responsible for ensuring that all adverse events (as defined in 
Section 9.1 and as further specified below) and adverse events of interest  
(Section 7.11) observed by [CONTACT_883472] 
(excluding cohort 3 subjects), treatment, through the first 6-month safety  follow up visit  
as well as through the end of safety follow -up phase for adverse events of interest  
(Section 3.4.2) are collected and recorded in the subjects‚Äô medical records and in 
designated study documents ( ie, eCRF, and, on the serious adverse event report 
(SAER) form for serious adverse events).  These adverse events  will include all serious  
and non serious adverse events (as defined in Sections 9.1.1 and 9.1.2) that occur after  
the subject has signed the informed consent form .   
The following adverse event attributes must be assigned by [CONTACT_093]:  adverse 
event diagnosis or syndrome(s) (if known, signs or symptoms if not known); event description (with detail appropriate to the event); dates of onset and resolution; severity; 
assessment of relatedness to investigational product and action taken.  Diagnoses or 
syndromes -rather than signs or symptoms -should be recorded.  The investigator may be 
asked to provide follow-up information, discharge summaries, and extracts from medical 
records or e CRFs.  
If applicable, the relationship of the adverse event to the investigational product will be 
assessed by [CONTACT_7859]:  ‚ÄúIs there a reasonable possibility that the event may have been caused by [CONTACT_7198]?‚Äù  The investigator should respond 
to this question with either Yes or No. 
The severity grading scale used in this study is described in  Appendix  B. 
Medicall y significant adverse events considered related to the investigational product by 
[CONTACT_883473].  
It will be left to the investigator‚Äôs clinical judgment to determine whether an adverse 
event is related and of sufficient severity to require the subject‚Äôs removal from treatment 
or from the study.  A subject may also voluntarily withdraw from treatment due to what 
he or she perceives as an intolerable adverse event.  If either of these situations arises, the subject should be strongly encouraged to undergo an end-of-study assessment and be under medical supervision until symptoms cease or the condition becomes stable. 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236018] be recorded on a Serious Adverse Event Report F orm ( Appendix  D) and 
faxed to [COMPANY_010] Global Safety.  Relevant medical records should be faxed to [COMPANY_010] 
Global Safety as soon as they become available; autopsy reports should be provided for 
deaths if available.   
For all deaths , available autopsy reports and relevant medical reports should be faxed to 
[COMPANY_010] Global Safety.   
If a subject is permanently withdrawn from the study or safety follow-up because of a 
serious adverse event, this information must be included in the initial or follow -up 
Serious Adverse Event Report Form as well as the End of Study  or End of Safety 
Follow -up eCRF.  
[COMPANY_010] will report serious adverse events (SAEs) and suspected unexpected serious 
adverse reactions (S[LOCATION_003]RS) as required to regulatory authorities, 
investigators/institutions and ethics committees  in compliance with all applicable 
regulatory requirements and ICH GCP  Guidelines. 
The investigator should notify the appropriate IRB or ethics committee of serious adverse events occurring at the site and other adverse event reports received from [COMPANY_010], in accordance with local procedures and statutes.  
9.[ADDRESS_1236019]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236020] dose with the exception of subjects who are receiving a 
commercial Xgeva in the s afety follow -up phase.  For those subjects investigators 
should report pregnancies until the end of the safety follow -up phase.  
For both situation/ scenarios t he pregnancy should be reported to [COMPANY_010] G lobal 
Patient Safety  within 24 hours of the investigator‚Äôs knowledge of the event of a 
pregnancy.  Report a pregnancy on the Pregnancy Notification Worksheet ( Appendix  C).  
[COMPANY_010] will seek to follow the pregnant woman throughout her pregnancy and her baby 
[CONTACT_8622] [ADDRESS_1236021] dose.  For those subjects receiving a commercial Xgeva in 
the safety follow -up phase investigators should report lactation cases until the 
end of the safety follow -up phase.  
Any lactation case should be reported to [COMPANY_010] G lobal Patient Safety  within 24 hours 
of the investigator‚Äôs knowledge of event.  Report a lactation case on the Lactation 
Notification Worksheet (Appendix  G). 
9.4.[ADDRESS_1236022] (eg, oral surgeon).  All subjects 
presenting with new or unusual thigh, hip, or groin pain should be evaluated for a suspected adverse event of atypi[INVESTIGATOR_147167].  
Adverse events reported as ONJ or atypi[INVESTIGATOR_883445]-defined criteria for ONJ or atypi[INVESTIGATOR_883446].  [COMPANY_010] will request the investigating site to provide all available source 
documents surrounding that event to be reviewed by [CONTACT_883474] 
3URGXFW'HQRVXPDE$0*
3URWRFRO1XPEHU'DWH6HSWHPEHU 3DJHRI
&21),'(17,$/FRPPLWWHH,IDQHYHQWLVDGMXGLFDWHGSRVLWLYHIRU21-WKHLQ YHVWLJDWRUZLOOEH
QRWLILHGRIWKHDGMXGLFDWLRQGHFLVLRQ
 67$7,67,&$/&216,'(5$7,216
 6WXG\'HVLJQ7KLVLVDSKDVHLQWHUQDWLRQDO PXOWLFHQWHURSHQODEHOVWXG \LQVXEMHFWVZLWK*&7%RI
ERQHUHFHLYLQJGHQRVXPDEDWDGRVHRIPJ6&4:ZLWKDORD GLQJGRVHRIPJ
6&RQVWXG\GD\VDQG
7KHUHDUHFRKRUWVLQWKLVVWXG\
x&RKRUW6XEMHFWVZLWKVXUJLFDOO\XQVDOYDJHDEOHGLVHDVHHJ VDFUDOVSLQDO*&7%
RUPXOWLSOHOHVLRQVLQFOXGLQJSXOPRQDU\PHWDVWDVHV
x&RKRUW6XEMHFWVZLWKVXUJLFDOO\VDOYDJHDEOHGLVHDVHZKRVHS ODQQHGRQVWXG\
VXUJHU\LVDVVRFLDWHGZLWKVHYHU HPRUELGLW\HJMRLQWUHVHFWLR QOLPEDPSXWDWLRQRU
KHPLSHOYHFWRP\
x&RKRUW6XEMHFWVZKRDUHFX UUHQWO\SDUWLFLSDWLQJLQ$PJHQV WXG\JLDQW
FHOOWXPRUVWXG\ZKRDUHHOLJLEOHWRHQUROO
 6WXG\(QGSRLQWV6XEVHWVDQG&RYDULDWHV
 3ULPDU\(QGSRLQW
7KHSULPDU\HQGSRLQWLVWKHVDIHW\SURILOHRIGHQRVXPDEFKDUDFW HUL]HGLQWHUPVRIWKH
W\SHIUHTXHQF\DQGVHYHULW\RIDGY HUVHHYHQWVDQGODERUDWRU\ DEQRUPDOLWLHVIRUHDFK
FRKRUW
 6HFRQGDU\(QGSRLQW
7KHVHFRQGDU\HQGSRLQWVLQFOXGH
xWLPHWRGLVHDVHSURJU HVVLRQIRUFRKRUW
xSURSRUWLRQRIVXEMHFWVZLWKRXWDQ\V XUJHU\DWPRQWKIRUFRKRU W
xVHUXPGHQRVXPDEWURXJKFRQFHQWUDWLRQV3.VXEVHW
CCI
3URGXFW'HQRVXPDE$0*
3URWRFRO1XPEHU'DWH6HSWHPEHU 3DJHRI
&21),'(17,$/ 6XEVHWV
7KHVDIHW\DQDO\VLVVHWIRUDGYHUVHHYHQWVDQGODESDUDPHWHUV LQFOXGHVDOOHQUROOHG
VXEMHFWVZKRUHFHLY HGDWOHDVWRQHGRVHRIGHQRVXPDE7KHHIIL FDF\DQDO\VLVVHW
LQFOXGHVDOOHQUROOHGVXEMHFWV ZKRZHUHHOLJLEOHIRUWKHVWXG\ DQGUHFHLYHGDWOHDVWRQH
GRVHRIGHQRVXPDE7KH352DQDO\VLVVHWL QFOXGHVDOOVXEMHFWV LQWKHHIILFDF\DQDO\VLV
VHWZKRKDGDWOHDVWRQH352DVVHVVPHQW7KHLQWHULPDQDO\VLV VHWLQFOXGHVWKHVDIHW\
HIILFDF\DQG352DQDO\VLVVHWVRI DOOHQUROOHGVXEMHFWVXSWR WKHWLPHRIWKHLQWHULP
DQDO\VHV
 6DPSOH6L]H&RQVLGHUDWLRQV
7KHVDPSOHVL]HIRUWKLVVWXG\L VGHWHUPLQHGE\WKHQXPEHURI* &7%VXEMHFWVZKR
TXDOLI\IRUWKHVWXG\7KHDYDLO DELOLW\RIVXEMHFWVPD\EHOLP LWHGE\WKHQXPEHURI
SDWLHQWVZLWKWKLVUDUHWXPRXU ZKRPHHWWKHLQFOXVLRQH[FOXVLRQ FULWHULD
)RUWKHH[SHFWHGVDPSOHVL]HRIVXEMHFWVWKHFRQILGHQF HLQWHUYDO&,EDVHGRQ
(;$&7PHWKRG IRUWKHLQFLGHQFHUDWHRIDSDUWLFXODUDGYHUVHHYHQWLVFDOFXOD WHGEHORZ
7DEOH,IQRQHRIWKHVXEMHFWVUHSRUWDSDUWLFXODUDGYHUVHHYHQWW KHQDWUXHLQFLGHQFH
UDWHRIPRUHWKDQLVXQOLNHO\IRUWKDWSDUWLFXODUDGYHUVH HYHQW
7DEOH(VWLPDWHG&RQILGHQFH,QWHUYDOIRU([DPSOH$GYHUVH (YHQW
,QFLGHQFH5DWHV
1XPEHURI
6XEMHFWV
5HSRUWLQJ$GYHUVH(YHQW$GYHUVH(YHQW,QFLGHQFH5DWH
(VWLPDWH
&,

  
  
  
  
  
  
  
  
  CCI
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236023] from the European Medicines Agency that 
included approximately 507 subjects and a median follow up time of 20.8 months.  
Additional  interim analyses may be conducted to monitor the ongoing safety of 
denosumab or to make decisions regarding the use of denosumab in the treatment of 
giant cell tumor of bone (GCTB). 
10.6 Planned Methods of Analysis  
10.6.1 General Approach/Considerations 
The statistical analysis in this open-label study will be descriptive in nature and no 
hypothesis testing will be performed.  All the efficacy  analyses will be conducted 
separately in each cohort and for cohorts 1 and 2 combined unless specified otherwise; 
and the safety analyses will be conducted for all cohorts combined.  The analyses  will be 
repeated for the adolescent population as  applicable.  Categorical data will be presented 
in the form of number and percentage.  Continuous data will be provided with the 
descriptive statistics (n, mean, standard deviation, median, 25
th percentile, 
75th percentile, minimum, and maximum).  The primary analysis will be conducted after 
all subjects have an opportunity to complete [ADDRESS_1236024] on this study, or  any worsening of adverse events initially experienced before 
initiation of this study.  This summary for adverse events will be performed for the following categories:  
‚Ä¢All adverse events
‚Ä¢Investigational product (IP)  related adverse events
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 44 of 69 
CONFIDENTIAL    ‚Ä¢ CTCAE grade 3, 4, or 5 adverse events  
‚Ä¢ IP related CTCAE grade 3, 4, or 5 adverse events  
‚Ä¢ Serious adverse events  
‚Ä¢ IP related serious adverse events  
‚Ä¢ Adverse events leading to study discontinuation 
‚Ä¢ IP related adverse events leading to study discontinuation 
‚Ä¢ Adverse events leading to investigational product discontinuation 
‚Ä¢ Fatal events  
Pharmacokinetic/ Pharmacodynamic Analyses 
Summary statistics for serum concentrations of denosumab will be provided for each 
timepoint (scheduled visit).  Summary statistics for the bone turnover markers, uNTx/Cr 
and sCTx, and their changes from baseline (absolute and % change) will be provided at 
scheduled visits. The analysis will be based on adolescent and adult subjects enrolled in the PK substudy receiving at least one dose of denosumab.   
Laboratory Parameters  
The analysis will be based on the combined sets of subjects receiving at least one dose 
of denosumab.  Summary statistics for lab values and their changes from baseline will 
be provided at scheduled visits.  Laboratory shift tables summarizing the worst changes 
in Common Terminology Criteria for adverse event (v3.0 or higher) grades between baseline and any study visits during the treatment period will be provided. 
Time to D isease Progression, T ime to D isease Recurrence, Progression F ree 
Survival, and T ime to Surgery 
Kaplan-Meier estimates will be graphically displayed.  K aplan-Meier event rates at 
various time points  (eg, month 3, month 6, etc ) with 2-sided confidence interval s will be 
summarized.  In addition, Kaplan-Meier estimates of quartiles (median, 25th and 
75
th percentiles) with 2-sided 95% confidence intervals will be calculated if applicable.  
Time to disease progression, time to disease recurrence, and p rogression free survival 
will be analyzed by [CONTACT_883475] [ADDRESS_1236025] -baseline, 
Proportion of Subjects Able to Undergo a L ess Morbid Surgical Procedure 
Compared With the Planned Surgical Procedure  
3URGXFW'HQRVXPDE$0*
3URWRFRO1XPEHU'DWH6HSWHPEHU 3DJHRI
&21),'(17,$/&UXGHHVWLPDWHVZLWKVLGHGH[DFWFRQILGHQFHLQWHUYDOVZLO OEHVX[COMPANY_003]UL]HG
3URSRUWLRQRIVXEMHFWVZLWKRXWDQ\VXUJHU\DQGSURSRUWLRQRIV XEMHFWVDEOHWRXQGHUJRD
OHVVPRUELGVXUJLFDOSURFHGXUHFRPSDUHGZLWKWKHSODQQHGVXUJLF DOSURFHGXUHZLOOEH
UHSRUWHGIRUFRKRUWRQO\3URSRUWLRQRIVXEMHFWVZLWKSDWKRO RJLFUHVSRQVHDQGWXPRU
DEVHQFHSRVWEDVHOLQHZLOOEHUHSRUWHGIRUWKRVHVXEMHFWVZLWK KLVWRSDWKRORJ\SURFHGXUHV
RQVWXG\E\FRKRUWDQGIRUFRKRUWVDQGFRPELQHG
5DGLRORJ\0HDVXUHPHQW
5DGLRORJ\FKDQJHZLOOEHVX[COMPANY_003]UL]HGGHVFULSWLYHO\RYHUWLPHE\ FRKRUWDQGIRU
FRKRUWVDQGFRPELQHG
'LVHDVH6WDWXV
'LVHDVHVWDWXVFKDQJHZLOOEHVX[COMPANY_003] UL]HGGHVFULSWLYHO\RYHUWLP HE\FRKRUWDQGIRU
FRKRUWVDQGFRPELQHG
&KDQJHLQ3DLQ6FRUHIURP%DVHOLQH
&KDQJHLQWKH%3,6)RXWFRPHVVFRUHVZRUVWSDLQVFRUHSDLQVH YHULW\VFRUHDQGSDLQ
LQWHUIHUHQFHVFRUHIURPEDVHOLQHDVZHOODVWKHUHFRUGHG%3, 6)RXWFRPHVVFRUHVZLOO
EHVX[COMPANY_003]UL]HGDWHDFKYLVLWXVLQJVX[COMPANY_003]U\VWDWLVWLFV
.DSODQ0HLHUFXUYHVUHIOHFWLQJ tSRLQWGHFUHDVHLQ¬µSDLQDWLWVZRUVW¬∂TXHVWLRQIURP
EDVHOLQH tSRLQWLQFUHDVHLQ¬µSDLQDWLWVZRUVW¬∂TXHVWLRQIURPEDVHOLQH DQG
!SRLQWLQ¬µSDLQDWLWVZRUVW¬∂TXHVWLRQLQVXEMHFWVZLWKEDV HOLQHdSRLQWV DQG
 VWURQJRSLRLGXVH ZLOOEHGHYHORSHG7KHVHHVWLPDWHVZLOOTXDQWLI\WKHWLPHWR
LPSURYHPHQWLQSDLQWKH WLPHWRZRUVHQLQJRISDLQ DQGWKHWLPHWRVWURQJRSLRLGXVH 
UHVSHFWLYHO\
 3ODQQHG0HWKRGVRI$QDO\VLVIRUWKH6DIHW\)ROORZXS3 KDVH
6DIHW\GDWDLQFOXGLQJ$(VDQG6$(VIURPWKHVDIHW\IROORZXSSK DVHZLOOEHVX[COMPANY_003]UL]HG
XVLQJWKHPHWKRGVGHVFULEHGLQ 6HFWLRQ 
 ,19(67,*$7,21$/352'8&7
 'HQRVXPDE
'HQRVXPDEZLOOEHVXSSOLHGDVDVWHULOHFOHDUFRORUOHVVWRVO LJKWO\\HOORZ
SUHVHUYDWLYHIUHHOLTXLGLQVLQJOHXVHP/JODVVYLDOVFRQW DLQLQJDGHOLYHUDEOH
GRVHRIP/7KHIRUPXODWLRQRILQYHVWLJDWLRQDOSURGXFWLV PJGHQRVXPDE
SHUP/IRUPXODWHGZLWK P0VRGLXPDFHWDWHDQG VRUELWRODWD S+RI  
,QYHVWLJDWLRQDOSURGXFWGHWDLOVIRUGHQRVXPDELQFOXGLQJODEHOL QJVWRUDJHSUHSDUDWLRQ
HWFDUHSURYLGHGLQWKH ,3,0C C CC
I
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236026]‚Äôs eCRF . 
11.[ADDRESS_1236027]‚Äôs investigational product 
compliance (eg, amount administered) will be recorded on the subject‚Äôs eCRF .     
12. REGULATORY OBLIGATIONS  
12.1 Informed Consent 
An initial generic informed consent and a Pediatric Assent Informed Consent form has 
been provided to the investigator for prepar ation of the informed consent document to be 
used at his or her site.  Updates to the template will be communicated by [CONTACT_883476].  The written informed consent document should be prepared in the language(s) of the potential patient population.  
Before a subject‚Äôs participation in the clinical study, the investigator is responsible for obtaining written informed consent from the subject / subject‚Äôs parent or legally 
acceptable representative after adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the study and before any protocol -specific screening 
procedures (with the exception of procedures performed as standard of care) or any 
investigational product is administered.   
A legally acceptable representative is an individual or other body authorized under 
applicable law to consent, on behalf of a prospective subject, to the subject‚Äôs participation in the clinical study.   
If applicable, the investigator is also responsible for asking the subject / subject‚Äôs par ent 
or legally acceptable representative if the subject agrees to have his/her primary care 
physician informed of the subject‚Äôs participation in the clinical study  and recording the 
subject‚Äôs preference in the medical chart.  If the subject / subject‚Äôs parent  or legally 
acceptable representative agrees to such notification, the investigator shall inform the subject‚Äôs primary care physician of the subject‚Äôs participation in the clinical study.  If the 
subject does not agree to such notification, the investigator shall not inform the subject‚Äôs primary care physician.  
The acquisition of informed consent if applicable, the subject‚Äôs / subject parent‚Äôs  or 
legally acceptable representative agreement or refusal of his/her notification of the primary care physician, should be documented in the subject‚Äôs medical records, and the 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236028] and by [CONTACT_28506] (not necessarily an investigator).  The original signed informed consent form should be retained in 
accordance with institutional policy, and a copy of the signed consent form should be 
provided to the subject / subject parent‚Äôs  or legally acceptable representative. 
If a potential subject is illiterate or  visually impaired and does not have a legally 
acceptable representative, the investigator must provide an impartial witness to read the 
informed consent form to the subject and must allow for questions.  Thereafter, both the 
subject and the witness must sign the informed consent form to attest that informed consent was freely given and understood.  
In this study, obtaining assent from the adolescent and consent from the parents or 
legally  authorized representative, as defined by [CONTACT_1769] , will apply.  An adolescent is 
defined as a person who has not attained the legal age for consent for  treatments or 
procedures involved in clinical investigations, under the applicable law of the jurisdiction 
in which the clinical investigation will take place.  The local  IEC/IRB  will determine the 
process for obtaining and documenting the assent process for pediatric  subjects, but 
should follow the guidelines established by [CONTACT_9930] (DHHS) Office of Human Research Protections guidelines, which state an 
explanation of the procedures involved in the study should be made in a language 
appropriate to the adolescent‚Äôs age, experience, maturity and condition.  
12.2 Independent Ethics Committee/Institutional Review Board 
A copy of the protocol, proposed informed consent form, Pediatric Assent form (if 
appropriate), other written subject information, and any proposed advertising material 
must be submitted to the IEC/IRB for written approval.  A copy of the written approval of 
the protocol and informed consent form must be received by [CONTACT_883477].  
The investigator must submit and, where necessary, obtain approval from the IEC/IRB 
for all subsequent protocol amendments and changes to the informed consent and 
Pediatric Assent form (if appropriate) documents.  The investigator should notify the IEC/IRB of deviations from the protocol or serious adverse events occurring at the site and other adverse event reports received from [COMPANY_010] Global Safety, in accordance with 
local procedures.  
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 48 of 69 
CONFIDENTIAL  The investigator will be responsible for obtaining annual IEC/IRB approval/renewal 
throughout the duration of the study.  Copi[INVESTIGATOR_8268]‚Äôs reports and the IEC/IRB‚Äôs continuance of approval must be sent to [COMPANY_010]. 
12.3 Prestudy Documentation Requirements 
The investigator is responsible for forwarding the following documents to [COMPANY_010] for 
review before study initiation from [COMPANY_010] or its designee can occur:  
‚Ä¢Signed and dated protocol signature [CONTACT_3264] ( Investigator‚Äôs Agreement)
‚Ä¢Copy of approved informed consent form  and Pediatric Assent Form (if appropriate)
‚Ä¢Copy of the IEC/IRB approval of the denosumab IB, protocol, consent form, and
subject information sheet, if applicable
‚Ä¢Up-to-date curricula vitae of principal investigator [INVESTIGATOR_188154]
‚Ä¢IEC/IRB composition and/or written statement that IEC/IRB is in compliance withregulations
‚Ä¢Laboratory normal ranges and documentation of laboratory certification (orequivalent, if applicable)
‚Ä¢Current subject/investigator indemnity insurance, if applicable
‚Ä¢Signed study contract
‚Ä¢Completed FDA form 1572 (or equivalent)
‚Ä¢Completed Financial Disclosure statements for the principal investigator, allsubinvestigators, and their spouses (legal partners) and dependent children
12.[ADDRESS_1236029]‚Äôs confidentiality is maintained.  On the 
eCRFs  or other documents submitted to [COMPANY_010] subjects should be identified by [CONTACT_883478].  Documents that are not for submission to [COMPANY_010] (eg, signed 
informed consent forms, Pediatric Assent form [if appropriate]) should be kept in strict 
confidence by [CONTACT_093].  
In compliance with Federal regulations/ICH GCP Guidelines, it is required that the 
investigator and institution permit authorized representatives of the company, of the regulatory agency(s), and the IEC/IRB  direct access to review the subject‚Äôs original 
medical records for verification of study-related procedures and data.  Direct access 
includes examining, analyzing, verifying, and reproducing any records and reports that 
are important to the evaluation of the study.  The investigator is obligated to inform and obtain the consent of the subject to permit named representatives to have access to his/her study -related records without violating the confidentiality of the subject.  
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 49 of 69 
CONFIDENTIAL  12.5 Investigator Signatory Obligations 
Each clinical study report should be signed by [CONTACT_1720], in the case of 
multicenter studies, the coordinating investigator. 
The coordinating investigator, identified by [CONTACT_11337], will either be: 
‚Ä¢a recognized expert in the therapeutic area
‚Ä¢an investigator who provided significant contributions to either the design or
interpretation of the study
‚Ä¢an investigator contributing a high number of eligible subjects
13. ADMINISTRATIVE AND LEGAL OBLIGATIONS  
13.[ADDRESS_1236030] be obtained for all protocol amendments and amendments to the 
informed consent and Pediatric Assent form (if appropriate) documents.  The IEC/IRB must be informed of all amendments and give approval.  The investigator must send a copy of the approval letter from the IEC/IRB to [COMPANY_010].  
Both [COMPANY_010] and the investigator reserve the right to terminate the study according to 
the study contract.  The investigator should notify the IEC/IRB in writing of the study‚Äôs 
completion or early termination and send a copy of the notification to [COMPANY_010].  
Subjects may be eligible for continued treatment with investigational product by [CONTACT_433449]‚Äôs regulatory mechanism.  
However, [COMPANY_010] reserves the unilateral right, at its sole discretion, to determine whether to supply the investigational product, and by [CONTACT_21971], after termination of the trial and before it is available commercially. 
13.[ADDRESS_1236031] of appropriately qualified persons to whom he/she has delegated study duties.  All persons authorized to make entries and/or corrections on eCRF s will be included on the [COMPANY_010] Delegation of Authority Form.  
Source documents are original documents, data, and records from which the subject‚Äôs eCRF  data are obtained.  These include but are not limited to hospi[INVESTIGATOR_1097], clinical 
and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, pathology reports, and correspondence.   
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 50 of 69 
CONFIDENTIAL  The investigator and study staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation, suitable for 
inspection at any time by [CONTACT_21972]/or applicable regulatory 
authorities.  Elements should include: 
‚Ä¢Subject files containing completed eCRF s (data disc is provided at study closure)
and informed consent forms  and Pediatric Assent form (if appropriate)
‚Ä¢Study files containing the subject identification list, protocol with all amendments,
investigator‚Äôs brochure, copi[INVESTIGATOR_21892] (see Section 12.3), and all
correspondence to and from the IEC/IRB and [COMPANY_010].
‚Ä¢Proof of receipt, Investigational Product Accountability Record, Return of
Investigational Product for Destruction, Final Investigational Product ReconciliationStatement, and all drug- related correspondence
In addition, all original source documents supporting entries in the eCRFs  must be 
maintained and be readily available. 
No study document should be destroyed without prior written agreement between 
[COMPANY_010] and the investigator.  Should the investigator wish to assign the study records to 
another party or move them to another location, he/she must notify [COMPANY_010] in writing of 
the new responsible person and/or the new locati on. 
13.[ADDRESS_1236032] confidentiality is respected.  
The [COMPANY_010] monitor is responsible for verifying the eCRFs at regular intervals throughout 
the study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research.  The 
monitor should have access to subject medical records and other study -related records 
needed to verify the entries on the eCRFs . 
The investigator agrees to cooperate with the monitor to ensure that any problems 
detected in the course of these monitoring visits, including delays in completing eCRFs , 
are resolved. 
In accordance with ICH GCP and the sponsor‚Äôs audit plans, this study may be selected 
for audit by [CONTACT_21975]‚Äôs Clinical Quality Assurance Department (or designees).  Inspection of site facilities (eg, pharmacy, drug storage areas, laboratories) 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236033] and 
compliance with the protocol, ICH GCP, and applicable regulatory requi rements. 
All data capture for this study is planned to be electronic, however if necessary data 
capture may be performed utilizing paper CRFs: 
‚Ä¢ Corrections to paper forms will be made by a single line stroke through the error and 
insertion of the correction above or beside the error.  The change must be initialed 
and dated by [CONTACT_1720] a member of the study staff authorized by [CONTACT_883479].  No erasures, correction 
fluid, or tape may be used.   
‚Ä¢ Correcti ons to electronic forms will be automatically documented through the 
software‚Äôs ‚Äúaudit trail‚Äù.  
‚Ä¢ To ensure the quality of clinical data across all subjects and sites, a clinical data 
management review will be performed on subject data received at [COMPANY_010].  Dur ing 
this review, subject data will be checked for consistency, omissions, and any 
apparent discrepancies.  In addition, the data will be reviewed for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data 
management review process, data queries and/or site notifications will be raised in 
the EDC system for site completion.  
‚Ä¢ EDC only:  The principal investigator [INVESTIGATOR_883447].  The principal investigator [INVESTIGATOR_883448].  These signatures will indicate that the principal investigator [INVESTIGATOR_883449] e CRFs, the data queries, and the site notifications, and 
agrees with the content.  P aper output of the e CRF is available should the 
Investigator or the IEC/IRB require hard copy output for review, signature, and 
storage at the study site.  
‚Ä¢ [COMPANY_010]‚Äôs clinical data management department or designees will correct the database for the following e CRF issues without notification to site staff:  
‚àí misspellings that do not change the meaning of the word (excluding adverse 
events and medications)  
‚àí location of data recorded on an incorrect eCRF  (eg, moving lab data from 
general comments to the appropriate lab table)  
‚àí date errors that occur into the new year  
‚àí standard time to 24-hour clock  
‚àí temperature unit errors (Fahrenheit vs Centigrade)  
‚àí weight unit errors (pounds vs kilograms) if a baseline weight has been established  
‚àí height unit errors (in. vs cm) 
‚àí administrative data (eg, event names for unscheduled visits or retests)  
‚àí clarifying ‚Äúother, specify‚Äù if data are provided (eg, race, physical exam)  
‚àí if both the end date and a status of continuing is indicated (eg, for adverse events, concomitant medication, hospi[INVESTIGATOR_059]), the end date will supersede 
‚àí deletion of obvious duplicate data (eg, same results sent twice with the same date but different clinical planned events ‚Äîweek 4 and early termination)  
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 52 of 69 
CONFIDENTIAL  ‚àí for adverse events that record action taken code = 01 (none) and any other 
action code, 01 (none) may be deleted as it is superseded by [CONTACT_883480]  
‚àí if equivalent units or terms are recorded instead of the acceptable [COMPANY_010] standard (eg, cc for mL, SQ for SC route, Not Examined for Not Done), the 
[COMPANY_010] units or terms will be used  
‚àí if the answer to a YES or NO question is blank or obviously incorrect (eg, 
Answers to the following questions do not reflect the data that are recorded or missing:  Were there any adverse events?  Concomitant medications?  Hospi[INVESTIGATOR_602]?)  
‚àí correct e CRF page numbers  
13.4 Language 
Electronic case report forms (eCRFs) must be completed in English.  
All written information and other material to be used by [CONTACT_33262].  Consult the country -specific requirements for language requirements. 
13.5 Publication Policy  
To coordinate dissemination of data from this study, [COMPANY_010] encourages the formation of a publication committee consisting of several principal investigators and appropriate 
[COMPANY_010] staff.  The committee is expected to solicit input and assistance from other 
investigators and [COMPANY_010] staff as appropriate.  Membership on the committee (both for investigators and [COMPANY_010] staff) does not guarantee authorship-the criteria described below should be met for every publication. 
Authorship of any publications resulting from this study will be determined on the basis 
of the Uniform Requirement for Manuscripts Submitted to Biomedical Journals 
(International Committee of Medical Journal Editors, 2005), which states: 
‚Ä¢Authorship credit should be based on (1) substantial contributions to conception and
design, acquisition of data, or analysis and interpretation of data; (2) drafting the
article or revising it critically for important intellectual content; (3) final approval of the
version to be published.  Authors should meet conditions 1, 2, and 3.
‚Ä¢When a large, multicenter group has conducted the work, the group should identify
the individuals who accept direct responsibility for the manuscript.  These individuals
should fully meet the criteria for authorship defined above.
‚Ä¢Acquisition of funding, collection of data, or general supervision of the research
group, alone, does not justify authorship.
‚Ä¢All persons designated as authors should qualify for authorship, and all those who
qualify should be listed.
‚Ä¢Each author should have participated sufficiently in the work to take publicresponsibility for appropriate portions of the content.
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 53 of 69 
CONFIDENTIAL  All publications (eg, manuscripts, abstracts, oral/slide presentations, book c hapters) 
based on this study must be submitted to [COMPANY_010] for corporate review.  The Clinical 
Study Agreement among the institution, principal investigator, and [COMPANY_010] Inc. will detail 
the procedures for, and timing of, [COMPANY_010] Inc.‚Äôs  review of publications.  
13.[ADDRESS_1236034] 
and/or their insurance provider will be responsible for paying for the treatment.  No compensation is available from [COMPANY_010], other than that provided by l aw. 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 54 of 69 
CONFIDENTIAL  14. REFERENCES 
[COMPANY_010].  D enosumab Investigator‚Äôs Brochure 
Cheng, YY, Huang, L, Lee, M, Xu, K, Zheng, MH, Kumta, SM.  Bisphosphonates induce 
apoptosis of stromal tumor cells in giant cell tumor of bone.  Calcif Tissue Int.  
2004;75:71-77. 
Cleeland CS.  Pain assessment in Cancer.  In: Osaba D (ed).  Effect of Cancer on 
Quality of Life, Chapter 21.  CRC Press, Boca Raton FL, 1991. 
Elliott R, Kostenuik P, Chen C, et al.  Denosumab is a selective inhibitor of human 
receptor activator of NF- Œ∫Œ≤ ligand that blocks osteoclast formation in vitro and in vivo.  
Eur J Ca Suppl.  2006; 4:62. 
Kong Y -Y, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, 
lymphocyte development and lymph node organogenesis. Nature. 1999;315-323. 
Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor 
that controls osteoclastogenesis, and regulation of bone mass and calcium metabolism. 
Proc Natl Acad Sci [LOCATION_003]. 2000;97:1566-1571. 
Malawer M, Helman L, and Brian O‚Äô Sullivan .  In: Cancer: Principles & Practice of 
Oncology, 7th Edition.  Sarcomas of the Soft Tissues and Bone - Chapter 35.  Lippi[INVESTIGATOR_32199] & Wilkins. 2005  
Morgan T, Atkins GJ, Trivett MK, et al.  M olecular profiling of giant cell tumor of bone 
and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB.  
Am J Pathol .  2005;167(1):117-128.  
Nishimura M, Yuasa K, Mori K, et al.  Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact.  J Orthop Res .  2005;23(5):979-987. 
Oken et al.  Toxicity and Response Criteria of the Eastern Cooperative Oncology Group.  Am J Clin Onc .  5: 649 ‚Äì 655, 1982.  
Ominsky MS, Stolina M, Li X, Corbin TJ, Asuncion FJ, Barrero M, Niu Q -T, Dwyer D, 
Adamu S, Warmington KS, Grisanti M, Tan HL, Ke HZ, Simonat WS, Kostenuil PJ. One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption 
and increased vertebral bone volume, density and strength. J Bone Miner Res. 
2009;23:1234-1246. 
Roudier M, Kellar -Graney L, Huang LY, et al.  R ANKL and RANK expression in giant cell 
tumors of the bone: an immunohistochemical study.  Connective Tissue Oncology 
Society; 11th Annual CTOS Meeting. 2006; poster  
Szendroi, M.  Giant-cell tumour of bone.  Br Ed itorial  Society Bone Joint Surg.  
2004;86-B:5-12. 
Szendroi, M, Kiss, J., Antal, I.  Surgical treatment and prognostic factors in giant cell 
tumor of bone.  Acta Chir Orthop Traumatol Cech.  2003;70(3):142-[ADDRESS_1236035] development and function.  Nat Rev Genet. 2003;4:638-649. 
Zheng, MH, Robbins, P, Xu, J, Juang, L, Wood, DJ, Papadimitriou, JM.  The 
histogenesis of giant cell tumour of bone:  a model of interaction between neoplastic cells and osteoclasts.  Histol Histopathol .  2001;16:297-307. 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236036]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236037] 4 -wk period 
(days 1 to 28)  Treatment Period:  (Weeks)  
‚â§ 28 
days  ‚â§ 7 
days  Day 
1 Day 8  Day 
15 Day 29 
W5 W9 W13 W17 W21 W25 W29 W33 W37 W41 W45 End of 
Treatment  
Informed Consent12 X 
Medical history  X 
Pathology sample4 ‚Üê‚Üê‚Üê‚Üê‚Üê May be requested either during the study or at end of study for evaluation of histopathological response to 
treatment  ‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí  X 
Pathology reports3 X ‚Üê‚Üê‚Üê ‚Üê‚ÜêMust be attached to the subject‚Äôs medical record if performed as standard of care ‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí  X 
Imaging reports5 X ‚Üê‚Üê‚Üê‚Üê‚Üê‚ÜêMust be attached to the subject‚Äôs medical record if performed as standard of care ‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí 
Serum 
chemistries6,14 X X X X X  X X X X X X X X X X 
PE, Karnofsky7, 14 X X X X X X X X X X X X X X 
Disease Status7,14 X X X X X  X X X X X X X X X 
Oral Exam  X X X 
Pregnancy test8, 14 X X X X X X 
Antibody assay10 X X 
Pharmacokinetics15 X X X  X X X X X 
sCTx15 X X X X X X X X 
uNTx15 X X X  X X X X X 
Denosumab 
Administration1 X X X  X X X X X X X X X X X 
Patient Reported 
Outcomes9,13 X X X  X X X X X X X X 
Calcium / Vitamin D ‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê  All subjects should be adequately supplemented with calcium and Vitamin D ‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí 
AE Assessment11 X X ‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê Documented throughout the study ‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí  X 
Adverse Events of 
Interest  ‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚ÜêDocumented throughout the study ‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí X 
Con Med Review X X ‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê Documented throughout the study ‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí  X 
Page [ADDRESS_1236038]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  17 July 2015 Page 57 of 69 
CONFIDENTIAL    Protocol Activities  W49 W53 W57 W61 W65 W69 W73 W77 W81 W85 W89 W93 
and 
Q4W  Additional Tests 
at W97 and 
Q12W End of  
Treatment SFU2 
6 mo  SFU2 
12 mo SFU2 
Every 
12 mo 
Pathology sample4 ‚Üê‚Üê‚Üê‚Üê‚Üê  May be requested either during the study or at end of study for evaluation of histopathological 
response to treatment ‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí  X    
Pathology reports3 ‚Üê‚Üê‚Üê‚Üê‚Üê  Must be attached to the subject‚Äôs medical record if performed as standard of care  ‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí  X    
Imaging reports5 ‚Üê‚Üê‚Üê‚Üê‚Üê‚ÜêMust be attached to the subject‚Äôs medical record if performed as standard of care ‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí    
Serum 
chemistries6,14 X X X X X X X X X X X X  X    
PE, Karnofsky7, 14 X X X X X X X X X X X X  X X X  
Disease Status7,14 X X X X X X X X X X X X  X X X X 
Oral Exam X      X      Q24W X X   
Pregnancy test8, 14  X   X   X   X   X X X   
Antibody assay10              X X X  
Denosumab Administration
1 X X X X X X X X X X X X      
Patient Reported Outcomes
9,13 X   X   X   X   X X    
Calcium / Vitamin D ‚Üê‚Üê‚Üê‚Üê‚Üê Subjects should be adequately supplemented with calcium and Vitamin D ‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí     
AE Assessment11 ‚Üê‚Üê‚Üê‚Üê‚Üê Documented throughout treatment ‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí  X X   
Adverse events of interest ‚Üê‚Üê‚Üê‚Üê‚ÜêDocumented throughout the study ‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí X X X X 
Con Med Review ‚Üê‚Üê‚Üê‚Üê‚Üê Documented throughout treatment ‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí  X    
Page [ADDRESS_1236039]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  17 July 2015 Page 58 of 69 
CONFIDENTIAL    1. Subjects will continue to receive denosumab  until complete tumor resection (if applicable), disease progression physician‚Äôs or subject‚Äôs decision, or [COMPANY_010]‚Äôs 
decision to discontinue for any reason, or administration of any of the proscribed therapi[INVESTIGATOR_883450]:  
6.5.  Denosumab 120 mg is given by [CONTACT_883481] a 
1.7 mL injection of denosumab 70 mg/mL.  
2.  Safety Follow -Up:  For all subjects, including the PK substudy, data (treatment plus follow -up) will be collected until the end of the clinical study ( Section 3.4.2) 
which is when subjects enrolled before Amendment [ADDRESS_1236040] discontinued.  For subjects who 
discontinue(d) investigational product , safety follow -up visits will be conducted approximately every 6 months ( ¬± 1 month) after the End of Treatment visit 
(approximately [ADDRESS_1236041]) for the first year, then every 12 months ( ¬± 1 month).   The final safety follow -up visit will be 
conducted at the time of the end of the clinical study (Section 3.4.2) (even if this in not approximately 6 or 12 months since the previous  follow -up visit).  Prior to 
Amendment 7, for subjects who were in the safety follow -up of  study [ADDRESS_1236042] be conducted in the clinic.  Thereafter, subjects may be contact[CONTACT_883468] (eg telephone) to complete the assessments.  
3.  Histopathology reports confirming the diagnosis of GCT of bone and demonstrating active disease are to be obtained to determine eligibility at screening (not 
required for 20040215 subjects) .  All on -study reports are to be attached to the subject‚Äôs medical record  if performed as standard of care except at end of study 
where this may be requested.  
4.  Histopathology samples may be requested during or  at end of study.  
5.  Imaging report will be required at screening to confirm eligibility  (not required for 20040215 subjects) .  All on -study imaging reports  must be attached to the 
subject‚Äôs medical  record  if performed as standard of care.  Select historical and select on-study imaging performed as standard of care will be required to be 
sent to a central imaging vendor for evaluation of disease response.  
6.  Serum chemistries performed by [CONTACT_883482], calcium, albumin, magnesium and phosphorus.  
7.  Physical exam: The screening PE includes medical history, Karnofsky performance status, disease status, blood pressure, respi[INVESTIGATOR_697], temperature, weight and height. (After the subject has signed the informed consent and the medical history is recorded on the Medical and Surgical History eCRF, any new or 
worsening conditions should be reported on the Adverse Event eCRF, including any reported during the screening period.) Thereafter, only a disease status and 
Karnofsky performance status will be collected during the treatment phase of the study and at [ADDRESS_1236043] for women of childbearing potential is to be conducted at screening, on study (approximately every 12 weeks while receiving denosumab treatment) and during safety follow up (only at 6 months after EoT).  A urine/serum  pregnancy test must be done at baseline prior to first dose of denosumab if 
study day 1 is greater than 7 days from the pregnancy confirmation done at screening.  
9. Patient Reported Outcomes (PRO): Consist of BPI -SF. The BPI -SF will be administere d prior to each administration of investigational product at baseline, study 
days 8 and 15, then every 4 weeks (Q4W) from weeks 5 ‚Äì 25, then every 12 weeks (Q12W) to end of study.  
10. Serum for anti - denosumab antibod y assay  will be collected at baseline and as outlined on the schedule of assessments, including 2 samples during follow up 
(approximately 6 and 12 months after the end of study visit) .  Prior to Amendment 7, for subjects who were in the safety follow -up of study [ADDRESS_1236044]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236045] resolved.  
12. Informed consent may be obtained more than 28 days before Day 1 week 1.  
13. Cohort 3 subjects will  enroll at their next Q4W visit (based on their 20040215 schedule).  Informed consent will be obtained prior to any protocol specific 
procedures; PROs will be collected at their next Q12W assessment visit.  
14. Prior to Amendment 7, for subjects who were in the safety follow -up of study 20040215 and are e nrolling in this study, serum chemistries, physical examination, 
disease status, Karnofsky performance status,and pregnancy testing are not required during the safety follow- up.  Upon the approval of Amendment 7, subjects 
that enrolled in 20062004 from the 20040215 study will also follow the 20062004 schedule, and complete the assessments as directed in Appendix  A. 
15. Pharmacokinetic Substudy ‚Äì Approximately 10 adolescent and approximately 10 adult subjects will contribute to the PK substudy.  Samples for pharmacokinetic, 
uNTx, and sCTx analysis on Study Day 1 will be obtained prior to IP administration.  Subjects enrolled in the PK substudy will be followed (treatment plus 
follow -up) until all subjects enrolled before Amendment [ADDRESS_1236046]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September 2015  Page 60 of 69 
CONFIDENTIAL  Appendix B .  Adverse Event Severity Scoring System  
The Common Terminology Criteria for Adverse Events (CTCAE, version 3.0) are 
available at the following link:   
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.
pdf 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236047]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236048]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date: 1 5 September  2015  Page 63 of 69 
CONFIDENTIAL    A 
20062004 Clinical Trial Serious Adverse Event Report ‚Äì Phase 1 ‚Äì4 
Notify [COMPANY_010] Within 24 Hours of knowledge of the event  ÔÅ±New 
ÔÅ±Follow-up  
 
1. SITE INFORMATION  
Site Number  Investigator  
 Country  Date of Report  
Day          Month           Year 
  
     
Reporter  
 
 Phone  Number  
(              )  Fax Number  
(              )  
2. SUBJECT INFORMATION  
Subject ID Number  Date of Birth  
Day          Month           Year 
 Sex 
‚ñ°F  ‚ñ°M 
 Race  
 
            
3. SERIOUS ADVERSE EVENT - Information in this section must also be entered on the Serious Adverse Event Summary CRF  
Provide the date the Investigator became aware of this Serious Adverse Event Information :   Day_____Month____Year ______  
Serious Adverse Event Diagnosis or 
Syndrome 
If diagnosis is unknown, enter Signs / 
Symptoms 
When Final Diagnosis is known, enter as 
Adverse Event  
 
List one event per line.  If event is fatal, 
enter the Cause of Death.  Entry of  
‚ÄúDeath‚Äù is not acceptable, as this is an 
outcome.  Date Started  Date Ended  Check 
only if 
event    
occurred 
before 
first dose 
of IP Enter 
Serious  
Criteria 
code 
 
(see 
codes 
below)  Relationship  
Is there a  
reasonable  
possibility  that the 
event  
may have been 
caused by  
[CONTACT_431929]? If yes see 
section [ADDRESS_1236049] been caused 
by 
[CONTACT_883483]?  Outcome  
of Event  
 
01 Resolved  
02 Resolving  
03 Not  resolved 
04 Fatal Check only if event is 
related to  
study  
procedure  
eg, biopsy  
Day     Month     Year  Day     Month     Year  NoÔÉº YesÔÉº  
No
ÔÉº Yes
ÔÉº If Yes, 
what 
device?  
 
            
 
            
 
            
 
            
Serious 
Criteria:  01 Fatal  
02 Immediately life-threatening  03 Required hospi[INVESTIGATOR_059]  
04 Prolonged hospi[INVESTIGATOR_059] 05 Persistent or significant disability /incapacity  
06 Congenital anomaly / birth defect [ADDRESS_1236050]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date: [ADDRESS_1236051] hospi[INVESTIGATOR_057]? ‚ñ°No  ‚ñ°Yes, If yes, please complete date(s):    
5. INVESTIGATIONAL PRODUCT (IP)  
 Initial Start Date  Prior to, or at time of Event  Action Taken with Product  
01 Still being Administered  
02 Permanently discontinued  
03 Withheld  Day       Month       Year  Date of Dose  Dose  Route  Frequency  
Day       Month       Year  
<<IMP>>  
‚ñ°ÔÉºBlinded ‚ñ°ÔÉºOpen Label  
      
6. CONCOMITANT M EDICATIONS (eg, chemotherapy)        Any Concomit ant Medications?  ÔÅ± No ÔÅ±  Yes,  If yes, please complete:  
Medication Name(s)  Start Date  Stop Date  Co-suspect  Continuing  Dose  Route Freq.  Treatment Med  
Day        Month        Year  Day        Month        Year  NoÔÉº YesÔÉº NoÔÉº YesÔÉº NoÔÉº YesÔÉº 
 
            
 
            
 
            
 
            
 
            
 Site Number  Subject ID Number   
                  
7.  RELEVANT MEDICAL HISTORY (include dates, allergies and any  relevant prior therapy)  
 
 
 
 
 
 
 
 
8.  RELEVANT LABORATORY VALUES  (include baseline values)   Any Relevant Laboratory values? ‚ñ° No ‚ñ° Yes, If yes, please complete:  
Date  Test           
Unit           
Day            Month            Year           
 
 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date: 1 5 September  2015  Page 65 of 69 
CONFIDENTIAL               
           
           
           
           
           
           
9.  OTHER RELEVANT TESTS (diagnostics and procedures)                 Any Other Relevant tests?    ‚ñ° No   ‚ñ° Yes,  If yes, please complete:  
Date  Additional Tests  Results  Units  Day        Month        Year 
 
    
 
    
 
    
10.  CASE DESCRIPTION (Provide narrative details of events listed in section 3) For each event in section 3, where relationship=Yes, 
please provide rationale.  
 
 
 
 
 
 
 
Signature [CONTACT_883489]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2015  Page 66 of 69 
CONFIDENTIAL  Appendix E.  Karnofsky  Performance Status and Eastern Cooperative Oncology 
Group (ECOG) Performance Status 
Karnofsky  Performance Status 
100%  - Normal; no complaints; no evidence of disease.  
90% - Able to carry on normal activity; minor signs or symptoms of disease.  
80% - Normal activity with effort; some signs or symptoms of disease. 
70% - Cares for self, unable to carry on normal activity or do active work.  
60% - Requires occasional assistance, but is able to care for most personal needs.  
50% - Requires considerable assistance and frequent medical care.  
40% - Severely disabled; hospi[INVESTIGATOR_374], although death not imminent.  
30% - Severely disabled; hospi[INVESTIGATOR_20545]; active support treatment is  
  necessary.  
20% - Very sick; hospi[INVESTIGATOR_20545]; active support treatment is  necessary.  
10% - Moribund; fatal processes progressing rapi[INVESTIGATOR_375].  
0% - Dead.  
ECOG Scale  Performance Status  
0 - Fully active, able to carry out all pre- disease performance without restriction.  
1 - Restricted in physically strenuous activity, but ambulatory and able to carry out  
work of a light or sedentary nature, (e.g.  light housework, office work).  
2 - Ambulatory and capable of all self care, but unable to carry out any work  
 activities.  Up and about more than 50% of waking hours.  
3 - Capable of only limited self- care, confined to bed or chair more than 50% of 
  waking hours.  
4 - Completely disabled.  Cannot carry out any self -care.  Totally confined to bed or  
  chair.  
5 - Dead.  
Karnofsky Score of 100 - 90% corresponds to ECOG 0 
Karnofsky Score of   80 - 70% corresponds to ECOG 1 
Karnofsky Score of   60 - 50% corresponds to ECOG 2 
Karnofsky Score of   40 - 30% corresponds to ECOG 3 
Karnofsky Score of   20 - 10% corresponds to ECOG 4 
Karnofsky Score of            0% corresponds to ECOG 5  
Oken et al.  Toxicity and Response Criteria of the Eastern Cooperative Oncology Group.  
Am J Clin Onc .  5: 649 ‚Äì 655, 1982.  
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2015  Page 67 of 69 
CONFIDENTIAL  Appendix F .  Sample Brief Pain Inventory - Short Form (BPI-SF) 

Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236052]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236053]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2015  Page 1 of 13 
CONFIDENTIAL  Amendment 8 
Protocol Title:  An Open-label, Multi-center, Phase [ADDRESS_1236054]-001606-16 
Date: 
Amendment 1:
 
Amendment 2: Amendment 2 (Superseding)  
Amendment 3: Amendment 4: 
Amendment 5: 
Amendment 6: 
Amendment 7: 
Amendment 8: 
Amendment 8 (Superseding):  [ADDRESS_1236055] 2011 
15 May 2013 
17 July 2015 
15 September 2015  
Rationale: 
‚Ä¢Safety follow -up period information was updated and adverse events of interest
were listed to align the protocol language with post marketing data collection
requirements and to increase compliance with long-term follow -up data
requirements.
‚Ä¢Interim analysis 4 was removed as it is not a regulatory requirement and no study
report is expected from this interim analysis per regulatory requirements.
‚Ä¢Pharmacy guide is obsolete and has been replaced by [CONTACT_883484].
‚Ä¢Medical history  section was updated for clarification and to align with other
sections of the protocol.
‚Ä¢The dose escalation and stoppi[INVESTIGATOR_883451] [ADDRESS_1236056] 21 days between doses.
‚Ä¢Calcium and Vitamin D information was updated to match Xgeva productinformation.
‚Ä¢The number of birth control methods and amount of washout time required
between the end of treatment and pregnancy or breastfeeding was updated to
align with the informed consent and current safety information.
‚Ä¢Pregnancy reporting was changed from the Pregnancy Surveillance Program to
[COMPANY_010] Global Patient Safety  as per current [COMPANY_010] standard.
‚Ä¢Administration, typographical  and formatting changes were made t hroughout the
protocol.
3URGXFW'HQRVXPDE$0*
3URWRFRO1XPEHU 
'DWH6HSWHPEHU 3DJHRI
&21),'(17,$/'HVFULSWLRQRI&KDQJHV DOOFKDQJHVWRWKH3URWRFRODUHLQGLFDWHGLQEROGWH[W
6HFWLRQ $OODSSOLFDEOHVHFWLRQVDQGKHDGHU
5HSODFH 0D\
:LWK 6HSWHPEHU 
6HFWLRQ &RYHUSDJH
5HSODFH &OLQLFDO5HVHDUFK6WXG\0DQDJHU
$PJHQ,QF(PDLO
3KRQH
)D[ 
:LWK &OLQLFDO5HV HDUFK6WXG\0DQDJHU
$PJHQ,QF(PDLO 
3KRQH
)D[
5HSODFH &OLQLFDO5HVHDUFK6WXG\0DQDJHU
$PJHQ/WG(PDLO3KRQH
)D[ 
:LWK &OLQLFDO5HVHDUFK6WXG\0DQDJHU
$PJHQ6S]RR 
(PDLO
3KRQH
)D[
$GG $PHQGPHQW-XO\
6HFWLRQ 3URWRFRO6\QRSVLV6WXG\'HVLJQ3DUDJUDSK
$GG 'XULQJWKHVDIHW\IROORZXSSKDVHVXEMHFWVZLOOEHDVNHGDERXW 
VHULRXVDGYHUVHHYHQWVDGYHUVHHYHQWVRILQWHUHVWDQGGLVHDVH 
WUHDWPHQWVDQGRXWFRPHV6HFWLRQ 
6HFWLRQ 3URWRFRO6\QRSVLV6DPSOH6L]H
'HOHWH DQGDPLQLPXPRIVXEMHFWVZLOOEHDGROHVFHQWV
6HFWLRQ 3URWRFRO6\QRSVLV([FOXVLRQ&ULWHULD
5HSODFH x6XEMHFWLVSUHJQDQWRUEUHDVWIHHGLQJRUSODQQLQJWREHFRPH
SUHJQDQWZLWKLQPRQWKVDIWHUWKHHQGRIWUHDWPHQW
x)HPDOHVXEMHFWRIFKLOGEHDULQJSRWHQWLDOLVQRWZLOOLQJWRXVH WZR
PHWKRGVRIKLJKO\HIIHFWLYHFRQWUDFHSWLRQGXULQJWUHDWPHQWDQG IRU
PRQWKVDIWHUWKHHQGRIWUHDWPHQW[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2015  Page 3 of 13 
CONFIDENTIAL    With: ‚Ä¢ Subjec t is pregnant or breast feeding, or planning to become 
pregnant within 5  months after the end of treatment 
‚Ä¢ Female subject of child bearing potential is not willing to use a highly 
effective method of contraception during treatment and for 5  months 
after the end of treatment 
  
Section:  Protocol Synopsis, Exclusion criteria for [ADDRESS_1236057]: ‚Ä¢ Subject is pregnant or breast feeding, or planning to become 
pregnant within 7 months after the end of treatment 
‚Ä¢ Female subject of child bearing potential  is not willing to use two 
methods of highly effective contraception during treatment and for 
7 months after the end of treatment 
With: ‚Ä¢ Subject is pregnant or breast feeding, or planning to become pregnant within 5  months after the end of treatment 
‚Ä¢ Female subject of child bearing potential is not willing to use a highly 
effective method of contraception during treatment and for 5  months 
after the end of treatment 
  
Section:  Protocol Synopsis, Investigational Product Dosage and Administration  
Replace: It is strongly recommended that subjects take daily supplementation of 
at least 500 mg of calcium and 400 IU of vitamin D, except in the case of 
pre-existing hypercalcemia. 
With: All subjects should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of v itamin D), 
except in the case of pre-existing hypercalcemia. 
  
Section:  Protocol Synopsis, Procedures, paragraph 2 
Add: The approval process is required for new enrolling subjects and 
subjects considered for retreatment. 
  
Section:  Protocol Synopsis, Procedures, paragraph 3 
Add: A copy of the standard of care imaging reports obtained within 
[ADDRESS_1236058]‚Äôs medical record. 
Delete: Imaging and 
Delete: collected throughout the study  
Add: Similar data from procedures performed as standard of care will be 
attached to the subject‚Äôs medical record 
  
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2015  Page 4 of 13 
CONFIDENTIAL    Section:  Protocol Synopsis, Statistical Considerations, paragraph 2 
Delete: An interim analysis will occur when at least [ADDRESS_1236059] had the 
opportunity to complete 5 years on study. 
Add: An unplanned interim analysis was performed in August [ADDRESS_1236060] from the European Medicines Agency that included approximately 507 subjects and a median follow up time 
of 20.8 months.  
  
Section:  Study Glossary  
Add: IPIM    Investigational Product Instruction Manual 
ONJ    Osteonecrosis of the jaw  
  
Section:  Study Term EOS  
Delete: trial 
Add: study  
  
Section:  Study Term EOT  
Replace: end of treatment visit 
With: End of T reatment visit 
  
Section:  Table of Contents, List of Appendices  
Delete: Appendix C   Pharmacy Guide 
Move subsequent appendices up one letter  
  
Section:  2.2.1  Clinical Experience With Denosumab in Giant Cell Tumor of Bone 
(GCTB) 
Replace: Study 20040215 is an ongoing Phase 2 proof of concept study 
investigating the potential role for denosumab in the treatment of GCTB.  
The study tests the hypothesis that denosumab, a RANKL inhibitor, can inhibit the growth and survival of tumor cells in patients with GCTB.   
With: The Phase 2 study, Study 20040215, investigated the potential role for 
denosumab in the treatment of GCTB.  The study tested the hypothesis 
that denosumab, a RANKL inhibitor, can inhibit the growth and survival of tumor cells in patients with GCTB.   
  
Section:  3.3  Number of Subjects, paragraph 2 
Delete: and a minimum of [ADDRESS_1236061]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2015  Page 5 of 13 
CONFIDENTIAL    Section:  3.4.2   End of Study (EOS), paragraph [ADDRESS_1236062]: trial 
With: study  
  
Section:  4.[ADDRESS_1236063]: ‚Ä¢ Subject is pregnant or breast feeding, or planning to become 
pregnant within 7 months after the end of treatment 
‚Ä¢ Female subject of child bearing potential is not willing to use two methods of highly effective contraception during treatment and for 7 months after the end of treatment 
With: 
‚Ä¢ Subject is pregnant or breast feeding, or planning to become 
pregnant within 5  months after the end of treatment 
‚Ä¢ Female subject of child bearing potential is not willing to u se a highly 
effective method of contraception during treatment and for 5  months 
after the end of treatment 
  
Section:  4.[ADDRESS_1236064]: ‚Ä¢ Subject is pregnant or breast feeding, or planning to become 
pregnant within 7 months after the end of treatment 
‚Ä¢ Female subject of child bearing potential is not willing to use two 
methods of highly effective contraception during treatment and for 
7 months after the end of treatment 
With: ‚Ä¢ Subject is pregnant or breast feeding, or planning to become 
pregnant within 5  months after the end of treatment 
‚Ä¢ Female subject of child bearing potential is not willing to use a highly 
effective method of contraception during treatment and for 5  months 
after the end of treatment 
  
Section:  5.   SUBJECT ENROLLMENT, Paragraph 4 
Add: The approval process is required for new enrolling subjects and 
subjects considered for retreatment . 
  
Section:  6.  TREATMENT PROCEDURES  
Replace: For further details regarding preparation and adminis tration of the 
investigational product, refer to Appendix C (Pharmacy Guide). 
With: For further details regarding preparation and administration of the investigational product, refer to the Investigational Product 
Instruction Manual (IPIM), which is a document external to this 
protocol. 
  
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2015  Page 6 of 13 
CONFIDENTIAL    Section:  6.[ADDRESS_1236065]: For Q4W doses, if a planned dose (eg, week 5, week 9, etc.) is delayed 
more than 7 calendar days, it will be considered a missed dose and 
recorded as such on the eCRF.  
With: For Q4W doses, the planned dose may be given up to [ADDRESS_1236066] 21 days between 
doses.  If a planned dose (eg, week 5, week 9, etc.) is delayed more 
than 7 calendar days, it will be considered a missed dose and recorded 
as such on the eCRF.  
 Paragraph 5 
Add: (ONJ)  
  
Section:  6.4  Concomitant Therapy (Calcium and Vitamin D Supplements)  
Replace: It is strongly recommended that subjects take daily supplementation of 
at least 500 mg of calcium and 400 IU of Vitamin D, except in the case 
of pre-existing hypercalcemia.   
With: All subjects should be adequately supplemented with calcium and Vitamin D ( at least 500 mg of calcium and 400 IU of Vitamin D ), except 
in the case of pre-existing hypercalcemia. 
  
Section:  7.[ADDRESS_1236067]: The subject‚Äôs medical history will be obtained prior to enrollment and 
recorded on the eCRF.  Detailed history of all pre-existing conditions must be documented on the eCRF (and in the source documents).  All major and minor significant illnesses, surgeries, and conditions that are 
both historical and present/ongoing at the time of first dose of 
investigational product will be obtained.   
With: The subject‚Äôs medical history will be obtained ‚â§ [ADDRESS_1236068] be documented on the eCRF (and in the 
source documents).  Any illness or medical condition that is ongoing 
at the time of the subject‚Äôs first dose of study drug should be 
noted.  Worsening of a pre-existing condition should be reported as an adverse event.   
  
Section:  7.[ADDRESS_1236069]: Refer to Appendix F for Karnofsky performance status criteria. 
With: Refer to Appendix E for Karnofsky performance status criteria. 
  
Section:  7.[ADDRESS_1236070]: A copy of imaging reports (eg, PET, CT, PET/CT, MRI, or X -ray) 
performed as standard of care must be provided to [COMPANY_010].   
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2015  Page 7 of 13 
CONFIDENTIAL    With: A copy of imaging reports (eg, PET, CT, PE T/CT, MRI, or X -ray) 
performed as standard of care must be attached to the subject‚Äôs 
medical record .   
  
Section:  7.[ADDRESS_1236071]: A copy of all available pathology reports obtained as standard of care  
must be provided to [COMPANY_010] including the surgical report of the GCTB 
target lesion resection.  Histopathology samples and reports may be 
requested at end of study.  
With: A copy of all available pathology reports obtained as standard of care  
must be attached to the subject‚Äôs medical record, incl uding the 
surgical report of the GCTB target lesion resection.  The histopathology 
samples and reports may be requested either during the study or at end of study  for evaluation of histopathological response to 
treatment . 
  
Section:  7.10  End of Treatmen t (EOT) Visit  
Replace: Each subject will have an end of treatment visit approximately [ADDRESS_1236072].  
With: Each subject will have an End of Treatment visit approximately [ADDRESS_1236073].  
  
Section:  7.11  Safety Follow -up Phase  
 Paragraph 1 
Add: During the safety follow -up phase, subjects will be asked about 
serious adverse events, adverse events of interest, and disease 
treatments and outcomes (Section 9. 2). 
 Paragrap h 5 
Add: Subjects will be asked to provide information regarding their GCTB 
status and current treatments.  Additionally, subjects will be asked 
if they have experienced any of the following adverse events of 
interest:  
‚Ä¢ ONJ 
‚Ä¢ Malignancy, including malignancy  in GCTB  
‚Ä¢ Atypi[INVESTIGATOR_883452], 
specific additional information will be requested/collected as necessary according to each type of event.  The additional 
information will include, but  is not limited to:    
‚Ä¢ ONJ:  dental records; information will be sent for 
adjudication by [CONTACT_155975] (see Section 9.4.1) 
‚Ä¢ Malignancy (including malignancy in GCTB ):  pathology 
reports  
‚Ä¢ Atypi[INVESTIGATOR_147167]:  x-ray or other imaging; 
medical/sur gical records.  Information will be sent for 
adjudication by [CONTACT_155975]  (see Section 9.4.1 ). 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  [ADDRESS_1236074] has experienced any serious adverse event 
(Section 9.1.2), information is to be collected and reported (see 
Section 9.3). 
If the subject has been receiving treatment with commercial denosumab (XGEVA), or any other [COMPANY_010] product as standard of care for GCTB or any other condition, Adverse Drug Reactions 
related to that product will be collected . 
  
Section:  8.[ADDRESS_1236075]: ‚Ä¢ pregnancy (report on Pregnancy Notification Worksheet, see  
Appendix  D)  
With ‚Ä¢ pregnancy (report on Pregnancy Notification Worksheet, see Appendix C )  
  
Section:  9.1.[ADDRESS_1236076]: Pregnancy is not considered an adverse event (see Appendix D for 
reporting any pregnancy).  
With: Pregnancy is not considered an adverse event (see Appendix C  for 
reporting any pregnancy). 
  
Section:  9.[ADDRESS_1236077]: The investigator is responsible for ensuring that all adverse events (as 
defined in Section 9.1 and as further specified below) observed by [CONTACT_883485] (excluding cohort 3 subjects), treatment and through the first 6 month safety follow 
up visit of the study are collected and recorded in the subjects‚Äô medical records and in designated study documents (ie, eCRF, and, on the 
serious adverse event report (SAER) form for serious adverse events). 
With: The investigator is responsible for ensuring that all adverse events (as 
defined in Section 9.1 and as further specified below) and adverse events of interest  (Section 7.11) observed by [CONTACT_883486] (excluding cohort 3 subjects), 
treatment, through the first 6-month safety follow up visit as well as 
through the end of safety follow -up phase for adverse events of 
interest (Section 3.4.2) are collected and recorded in the subjects‚Äô 
medical records and in designated study documents (ie, eCRF, and, on 
the serious adverse event report (SAER) form for serious adverse events). 
  
Section:  9.[ADDRESS_1236078]: Initial serious adverse event information and all amendments or additions must be recorded on a Serious Adverse Event Report F orm 
(Appendix E) and faxed to [COMPANY_010] Global Safety. 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2015  Page 9 of 13 
CONFIDENTIAL    With: Initial serious adverse event information and all amendments or 
additions must be recorded on a Serious Adverse Event Report F orm 
(Appendix D ) and faxed to [COMPANY_010] Global Safety.  
  
Section:  9.[ADDRESS_1236079]: Throughout denosumab treatment and through [ADDRESS_1236080] dose of IP, the investigator should counsel subjects who are women of childbearing potential on the risks of pregnancy while receiving denosumab, and discuss methods to decrease the risk of becoming 
pregnant. 
With: Throughout denosumab treatment and through [ADDRESS_1236081]: In addition to reporting any pregnancies occurring during the study, 
investigators should monitor for  pregnancies that occur after the last 
dose of protocol -required therapi[INVESTIGATOR_44817] [ADDRESS_1236082] dose. 
The pregnancy should be reported to [COMPANY_010]‚Äôs global Pregnancy 
Surveillance Program within 24 hours of the investigator‚Äôs knowledge of the event of a pregnancy.  Report a pregnancy on the Pregnancy Notification Worksheet ( Appendix D).  The Pregnancy Surveillance 
Program (PSP) will seek to follow the pregnant woman throughout her pregnancy and her baby [CONTACT_8622] 12 months after birth. 
With: In addition to reporting any pregnancies occurring during the study, investigators should report  pregnancies that occur after the last dose of 
protocol -required therapi[INVESTIGATOR_44817] [ADDRESS_1236083] dose with 
the exception of subjects who are receiving a commercial Xgeva in the safety follow -up phase.  For those subjects investigators 
should report pregnancies until the end of the safety follow -up 
phase. 
For both situation/ scenarios t he pregnancy should be reported to 
[COMPANY_010] G lobal Patient Safety  within 24 hours of the investigator‚Äôs 
knowledge of the event of a pregnancy.  Report a pregnancy on the 
Pregnancy Notification Worksheet ( Appendix C).  [COMPANY_010] will seek to 
follow the pregnant woman throughout her pregnancy and her baby [CONTACT_8622] [ADDRESS_1236084]: In addition to reporting a lactation case during the study, investigators should monitor for lactation cases that occur after the last dose of 
protocol -required therapi[INVESTIGATOR_44817] [ADDRESS_1236085] dose. 
Any lactation case should be reported to [COMPANY_010]‚Äôs global Lactation 
Surveillance Program (LSP) within 24 hours of the investigator‚Äôs knowledge of event.  Report a lactation case on the Lactation Notification Worksheet ( Appendix H).    
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2015  Page 10 of 13 
CONFIDENTIAL    With: In addition to reporting a lactation case during the study, investigators 
should report  lactation cases that occur after the last dose of 
protocol -required therapi[INVESTIGATOR_44817] [ADDRESS_1236086] dose.  For 
those subjects receiving a commercial Xgeva in the safety follow -up phase, investigators should report lactation cases until 
the end of the safety follow -up phase. 
Any lactation case should be reported to [COMPANY_010] G lobal Patient Safety  
within 24 hours of the investigator‚Äôs knowledge of event.  Report a lactation case on the Lactation Notification Worksheet ( Appendix G).   
  
Section:  9.4.1  Adjudication Process for Suspected Osteonecrosis of the Jaw and Suspected Atypi[INVESTIGATOR_883453], paragraphs 1 and 2 
Add: All subjects with an oral adverse event suspi[INVESTIGATOR_883454] a dentist or other qualified oral specialist (eg, oral surgeon).  All subjects presenting with new or unusual thigh, hip, or groin pain should be evaluated for a suspected adverse event of atypi[INVESTIGATOR_147167]. 
Adverse events reported as ONJ or atypi[INVESTIGATOR_883455]-defined criteria for ONJ or atypi[INVESTIGATOR_883456].  
[COMPANY_010] will request the investigating site to provide all available source documents surrounding that event to be reviewed by [CONTACT_883487].  If an event is adjudicated positive 
for ONJ, the investigator will be notified of the adjudication 
decision. 
  
Section:  10.[ADDRESS_1236087]: An interim analysis will occur when at least [ADDRESS_1236088] had the opportunity to complete 5 years on study.  
With: An unplanned interim analysis was performed in August [ADDRESS_1236089] from the European Medicines Agency that included approximately 507 subjects and a median follow up time 
of 20.8 months.  
  
Section:  10.6.2  Analysis of Key Study Endpoints  
Delete: The analysis of BPI-SF outcomes will employ a pi[INVESTIGATOR_883457] (Fairclough et al, 2004).  If analgesic use increases over time, the on-study analgesic score will be included as an additional covariate in 
the analysis.  
Replace: Change in pain score from baseline  
Kaplan-Meier curves reflecting 1) ‚â•  2-point decrease in ‚Äòpain at its worst‚Äô 
question from baseline, 2) ‚â• 2-point increase in ‚Äòpain at its worst‚Äô 
question from baseline, and 3) >  4-point in ‚Äòpain at its worst‚Äô questi on (in 
3URGXFW'HQRVXPDE$0*
3URWRFRO1XPEHU 
'DWH6HSWHPEHU 3DJHRI
&21),'(17,$/  VXEMHFWVZLWKEDVHOLQH dSRLQWVZLOOEHGHYHORSHG7KHVHHVWLPDWHV
ZLOOTXDQWLI\WKHWLPHWRLPSURYHPHQWLQSDLQDQGWKHWLPHWRZ RUVHQLQJ
RISDLQUHVSHFWLYHO\
:LWK &KDQJHLQ3DLQ6FRUHIURP%DVHOLQH
.DSODQ0HLHUFXUYHVUHIOHFWLQJ tSRLQWGHFUHDVHLQ¬µSDLQDWLWVZRUVW¬∂
TXHVWLRQIURPEDVHOLQH tSRLQWLQFUHDVHLQ¬µSDLQDWLWVZRUVW¬∂
TXHVWLRQIURPEDVHOLQHDQG!SRLQWLQ¬µSDLQDWLWVZRUVW¬∂ TXHVWLRQLQ
VXEMHFWVZLWKEDVHOLQH dSRLQWV DQGVWURQJRSLRLGXVH ZLOOEH
GHYHORSHG7KHVHHVWLPDWHVZLOOTXDQWLI\WKHWLPHWRLPSURYHPH QWLQ
SDLQWKHWLPHWRZRUVHQLQJRISDLQ DQGWKHWLPHWRVWURQJRSLRLGXVH 
UHVSHFWLYHO\
6HFWLRQ 'HQRVXPDESDUDJUDSK
5HSODFH 'HQRVXPDEZLOOEHSURYLGHGDVDVWHULOHFOHDUFRORUO HVVWRVOLJKWO\
\HOORZSUDFWLFDOO\IUHHIURPSDUWLFOHVSUHVHUYDWLYHIUHHOLTX LGLQ
RSHQODEHOVLQJOHXVHP /YLDOVFRQWDLQLQJP/RIPJ P/
GHQRVXPDE P0DFHWDWHDQG ZYVRUELWRODWDS+RI ,QYHVWLJDWLRQDOSURGXFWGHWDLOVIRUGHQRVXPDELQFOXGLQJODEHOL QJ
VWRUDJHSUHSDUDWLRQHWFDUHSURYLGHGLQWKH3KDUPDF\*XLGH$SSHQGL[&
:LWK 'HQRVXPDEZLOOEHVXSSOLHGDVDVWHULOHFOHDUFRORUOHVVWRVO LJKWO\
\HOORZSUHVHUYDWLYHIUHHOLTXLGLQVLQJOHXVHP/JODVVYL DOV
FRQWDLQLQJDGHOLYHUDEOHGRVHRIP/7KHIRUPXODWLRQRILQYHVWLJDWLRQDOSURGXFWLVPJGHQRVXPDESHUP/IRUPXODWHGZLWK P0VRGLXPDFHWDWHDQG VRUELWRODWDS+RI 
,QYHVWLJDWLRQDOSURGXFWGHWDLOVIRUGHQRVXPDELQFOXGLQJODEHOL QJ
VWRUDJHSUHSDUDWLRQHWFDUHSURYLGHGLQWKH ,3,0
6HFWLRQ 5()(5(1&(6'HOHWH )DLUFORXJK'/*DJQRQ'DQG3DSDGRSRXORV*3ODQQLQJ $QDO\VHVRI
4XDOLW\RI/LIH6WXGLHV$&DVH([DPSOHZLWK0LJUDLQH3URSK\OD[ LV
-%LRSKDUP6WDW 
6HFWLRQ $SSHQGL[$6FKHGXOHRI$ VVHVVPHQWV3DWKRORJ\VDPSOH
5HSODFH 7REHVXEPLWWHGLISHUIRUPHGDVVWDQGDUGRIFDUH
:LWK mmmmm 0D\EHUHTXHVWHGHLWKHUGXULQJWKHVWXG\RUDWHQGRI
VWXG\IRUHYDOXDWLRQRIKLVWRSDWKRORJLFDOUHVSRQVHWRWUHDWPHQW 
ooooooo 
C CC CCI
C C CC
I
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2015  Page 12 of 13 
CONFIDENTIAL    Section:  Appendix A, Schedule of Assessments, Imaging reports and pathology 
reports  
Replace: To be submitted if performed as standard of care  
With: Must be attached to the subject‚Äôs medical record if performed as 
standard of care 
Add: Adverse events of interest  
‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚ÜêDocumented throughout the 
study‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí 
X  in end of treatment box ; X in SFU [ADDRESS_1236090]: Calcium / Vitamin D:  Strongly recommended to be taken daily  
With: ‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê‚Üê  All subjects should be adequately 
supplemented with calcium and Vitamin D  ‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí‚Üí 
  
Section:  Appendix A, PE, Karnofsky  
Add: X at 6 and12 month SFU 
  
Section:  Appendix A, footnote [ADDRESS_1236091]: All on -study reports will be collected if performed as standard of care 
except at end of study where this may be requested. 
With: All on -study reports are to be attached to the subject‚Äôs medical 
record if performed as standard of care except at end of study where 
this may be requested.  
  
Section:  Appendix A, footnote 4  
Add: Histopathology samples may be requested during or at end of study. 
  
Section:  Appendix A, footnote [ADDRESS_1236092]: All on -study imaging reports will be collected if performed as standard of 
care. 
With: All on -study imaging reports must be attached to the subject‚Äôs 
medical record if performed as standard of care. 
  
Section:  Appendix A, footnote 7  
Add: Thereafter, only a disease status and Karnofsky performance status will 
be collected during the treatment phase of the study and at [ADDRESS_1236093]:  Denosumab (AMG 162)  
Protocol Number:  20062004  
Date:  15 September  2015  Page 13 of 13 
CONFIDENTIAL    Section:  Appendix A, footnote [ADDRESS_1236094]: EoS 
With: EoT 
  
Section:  Appendix A, footnote 11  
Add: Adverse events of interest will be followed through the last safety 
follow -up visit. 
  
Section:  Appendix C  
Replace: Appendix D.  Pregnancy Notification Worksheet  
With: Appendix C. Pregnancy Notification Worksheet  
  
Section:  Appendix D  
Replace: Appendix E.  Sample SAE Report Form  
With: Appendix D. Sample SAE Report Form  
New Form  
  
Section:  Appendices E , F, G  
Replace: Appendix F, G, H in title 
With: Appendix E, F, G , respectively  
 
Product:  Denosumab  (AMG 162)  
Protocol Number:  20062004  
Date:  17 July 2015  Page 1 of 13 
CONFIDENTIAL    Amendment 8 
Protocol Title:  An Open- label, Multi- center, Phase [ADDRESS_1236095]- 001606 -16 
 
Date:  
Amendment 1:  
Amendment 2:  
Amendment 2 (Superseding)  
Amendment 3:  
Amendment 4:  
Amendment 5:  
Amendment 6:  
Amendment 7:  
Amendment 8:  [ADDRESS_1236096] 2011  
15 May 2013 
17 July 2015 
 
Rationale:  
‚Ä¢ Safety follow -up period information was updated and adverse events of interest 
were listed to align the protocol language with post marketing data collection 
requirements and to increase compliance with long- term follow -up data 
requirements.  
‚Ä¢ Interim analysis 4 was removed as it is not a regulatory requirement and no study report is expected from this interim analysis per regulatory requirements.  
‚Ä¢ Pharmacy guide is obsolete and has been replaced by [CONTACT_883484].  
‚Ä¢ Medical history section was updated for clarification and to align with other 
sections of the protocol.  
‚Ä¢ The dose escalation and stoppi[INVESTIGATOR_883458] [ADDRESS_1236097] 21 days between doses. 
‚Ä¢ Calcium and Vitamin D i nformation was updated to match Xgeva product 
information.  
‚Ä¢ The number of birth control methods and amount of washout time required 
between the end of treatment and pregnancy or breastfeeding was updated to 
align with the informed consent  and current safety  information. 
‚Ä¢ Pregnancy reporting was changed from the Pregnancy Surveillance Program to 
[COMPANY_010] Global Patient Safety  as per current [COMPANY_010] standard.  
‚Ä¢ Administration, typographical  and formatting changes were made throughout the 
protocol.  
Product:  Denosumab (AMG 162) 
Protocol Number:  20062004  
Date:  15 May 2013  Page 72 of 99 
 Amendment 7:  Rationale and Summary of Amendment Changes  
An Open- label, Multi- center, Phase [ADDRESS_1236098] 2008- 001606 -16 
 15 May  2013 
Summary of Changes:   
The primary reason for the amendment is to include  pharmacokinetic analyses for an 
additional approximately 20 subjects, approximately 10 adolescents and 10 adults.  
Additionally, the end of the clinical trial is defined as  when subjects enrolled through 
November 2012 (before Amendment 7 ) complete a minimum of [ADDRESS_1236099] .  Safety follow -up visits are 
described.  
Additional changes include the following:  
‚Ä¢ Added objectives, endpoints, sample collection, and analyses consistent with the 
pharmacokinetic subset  
‚Ä¢ Clarified that subjects who rolled over from 20040215 will follow the 20062004 
schedule under Amendment 7  
‚Ä¢ Clarified the End of Treatment visit and Safety Follow -up visits  
‚Ä¢ Added oral examinations for all subjects, and provided additional guidance regarding IP dosing and oral/dental procedures  
‚Ä¢ Clarified safety reporting timelines  
‚Ä¢ Added updated pregnancy and lactation reporting section, with additional instructi ons 
regarding counseling women of childbearing potential on the risks of pregnancy while 
receiving denosumab and discussing methods to decrease the risk  
‚Ä¢ Removed references to and sections pertaining to Daiichi Sankyo Co Ltd and 
Japanese sites, as there are no Japanese sites in this trial.  
‚Ä¢ Typographic and formatting errors, redundancies, and inconsistencies were 
corrected  
3URGXFW'HQRVXPDE$0*
3URWRFRO1XPEHU¬±$PHQGPHQW
'DWH$XJXVW 3DJHRI
$PHQGPHQW5DWLRQDOHDQG6X[COMPANY_003]U\RI$PHQGPHQW&KDQJHV
$Q2SHQODEHO0XOWLFHQWHU3KDVH6WXG\RI'HQRVXPDELQ6XEM HFWVZLWK*LDQW
&HOO7XPRURI%RQH
$PJHQ3URWRFRO1XPEHU
(XGUD&7
,1'%%

 $XJXVW

5DWLRQDOH
7KHSULPDU\UHDVRQIRUWKLVDPHQGPHQWLVWRLQFUHDVHWKHVDPSOH VL]HIURP
DSSUR[LPDWHO\VXEMHFWVHQUROOHGWRDSSUR[LPDWHO\VXEMHF WVHQUROOHG7KLV
VDPSOHVL]HZLOODOORZDGGLWLRQDOVXEMHFWVWREHHQUROOHGRQWR WKLVVWXG\DOORZLQJJUHDWHU
VDIHW\GDWDWREHFROOHFWHGLQWKLVVXEMHFWSRSXODWLRQ
$GGLWLRQDOFKDQJHVLQFOXGHWKHIROORZLQJ
x 7\SRJUDSKLFDQGIRUPDWWLQJHUURUVUHGXQGDQFLHVDQGLQFRQVLVW HQFLHVZHUH
FRUUHFWHG

'HVFULSWLRQRI&KDQJHV
6HFWLRQ*OREDODOOFKDQJHVWRWKHSURWRFRODUHLQGLFDWHGLQEROGHGWH[W
&KDQJH$GG¬≥3URWRFRO$PHQGPHQW¬±$XJXVW¬¥

6HFWLRQ7LWOH3DJH
5HSODFH
.H\(86SRQVRU&RQWDFW &OLQLFDO5HVHDUFK6WXG\0DQDJHU
*OREDO6WXG\0DQDJHPHQW
$PJHQ/WG
3KRQH
)D[

:LWK
.H\(86SRQVRU&RQWDFW &OLQLFDO5HVHDUFK6WXG\0DQDJHU
*OREDO6WXG\0DQDJHPHQW
$PJHQ/WG
3KRQH
)D[



[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Product:  Denosum ab (AMG 162)  
Protocol Number:  20062004 ‚Äì Amendment 5  
Date:  05 May 2011  Page 68 of 74 
 Amendment 5:  Rationale and Summary of Amendment Changes  
An Open- label, Multi- center, Phase [ADDRESS_1236100] 2008- 001606 -16 
IND # BB -9838  
 
 05 May 2011 
 
Rationale:   
The primary reason for this amendment is to modify the exclusion criteria for 
contraception to include two methods of  highly effective contraception during treatment 
and for [ADDRESS_1236101] of care will be 
requested to be sent to a central imaging vendor for evaluation of disease res ponse.  
Additional changes include the following:  
‚Ä¢ The criteria for a subject to receive re- treatment has been clarified  
‚Ä¢ The frequency of interim analyses has been modified 
‚Ä¢ Typographic and formatting errors, redundancies, and inconsistencies were 
corrected  
 
Description of Changes  (all changes to the protocol are indicated in bolded text):  
Section:  Global  
Change:  Add ‚ÄúProtocol Amendment 5 ‚Äì 05 May 2011‚Äù  
 
Product:  Denosumab (AMG 162)  
Protocol Number:  20062004 ‚Äì Amendment 4  
Date:  15 November  2010  Page 68 of 72 
 Amendment 4:  Rationale and Summary of Amendment Changes 
An Open-label, Multi-center, Phase [ADDRESS_1236102] 2008-001606-16 
IND # BB-9838 
 
 15 November 2010 
 
Rationale:
The primary reason for this amendment is to increase the sample size from [ADDRESS_1236103] population.   
Additional changes include the following: 
‚Ä¢ The secondary Objectives have been clarified  
‚Ä¢ The analysis of safety data from the safety follow -up has been clarified in section 
10.6.3  
‚Ä¢ Typographic and formatting errors, redundancies, and inconsistencies were 
corrected  
 
 
Description of Changes
Section:   Global   (all changes to the protocol are indicated in bolded text):  
Change:  Add ‚ÄúProtocol Amendment 4 ‚Äì 15 November  2010 
 
Section:  Global  
Change:  change references to ‚Äúlong-term‚Äù follow -up to ‚Äúsafety‚Äù follow-up 
 
 Section:  Synopsis; Secondary Objectives: Replace:   
‚Ä¢ evaluation of the proportion of subjects who do not require surgery in denosumab 
treated subjects with salvageable GCTB who would have otherwise required en bloc excision (cohort 2)   
With: 
‚Ä¢ evaluation of the proportion of subjects who do not require surgery in denosumab 
treated subjects with salvageable GCTB (cohort 2)  
 
  
3URGXFW'HQRVXPDE$0*
3URWRFRO1XPEHU ¬±$PHQGPHQW
'DWH0D\ 3DJHRI
$PHQGPHQW5DWLRQDOHDQG6X[COMPANY_003]U\RI$PHQGPHQW&KDQJHV
$Q2SHQODEHO0XOWLFHQWHU3KDVH6WXG\RI'HQRVXPDELQ6XEM HFWVZLWK*LDQW
&HOO7XPRURI%RQH
$PJHQ3URWRFRO1XPEHU
(XGUD&7
,1'%%

 0D\
5DWLRQDOH

7KHSULPDU\UHDVRQIRUWKLVDPHQGPHQWLVWRDOORZVXEMHFWVIURP $PJHQ6WXG\
WRHQUROOLQWKLVVWXG\
$GGLWLRQDOFKDQJHVLQFOXGHWKHIROORZLQJ
‚Ä¢%DFNJURXQGVHFWLRQRQGHQRVXPDEZDVFKDQJHGWRUHIHUWRWKHPRV WFXUUHQWYHUVLRQ
RIWKH,QYHVWLJDWRU¬∂V%URFKXUH 
‚Ä¢ 7\SRJUDSKLFDQGIRUPDWWLQJHUURUVUHGXQGDQFLHV DQGLQFRQVLVWHQFLHVZHUH
FRUUHFWHG

CCI
Product:  Denosumab (AMG 162) 
Protocol Number:  20062004 ‚Äì Amendment 2 - Superseding Date:  11 January 2010 Page 68 of 91 
Amendment 2:  Rationale and Summary of Amendment Changes 
An Open-label, Multi-center, Phase [ADDRESS_1236104] 2008-001606-16 
IND # BB-9838 
 
 
 11 January 2010 
 Rationale:
  
The primary reason for this amendment is to increase the sample size from approximately [ADDRESS_1236105] population. 
Additional changes include the following: 
‚Ä¢ Clarification of secondary objective and endpoint to include subjects who do not 
require any surgery 
‚Ä¢ Addition of exploratory endpoints 
‚Ä¢ An eligibility criteria excluding women of child-be aring potential who are evidently 
pregnant or breast feeding has been
 added 
‚Ä¢ Addition of interim analyses corresponding with the increased sample size 
‚Ä¢ The schema, glossary, and schedule of assessments have been updated to 
reflect chan ges in the pr
otocol   
‚Ä¢ Other minor changes and typographical errors have been corrected throughout 
and highligh ted in bold t
ext 
 
 
Description of Changes  (all changes to the protocol are indicated in bolded text): 
Pages:  Global 
Change:  Add ‚ÄúProtocol Amendment 2 ‚Äì Superseding  Date:  11 January 2010 to each 
header 
 
Pages:  Global 
Change:  Case report form or CRF to eCRF 
 
Pages:  Global 
Change:  IRB to IEC/IRB  
 
 
 
Printed copy is not official record.                                          
 Product:  Denosumab 
Protocol Number:  20062004 Date:  12 December 2008  Page 1 of 18 
Amendment 1 
Protocol Title: 
 An Open-label, Multi-center, Phase [ADDRESS_1236106] 2008-001606-16 
IND # BB-9838 
 
  
Amendment 1 Date: 12 December 2008 
 Rationale:
  
The primary reason for this amendment is to include skeleta lly mature ad olescent s (ie, 
adolescents who have closed epi[INVESTIGATOR_728044]) into this study.  There have been rare 
reported cases of GCT of bone in adolescents.  Giant Cell Tumor of bone usually occurs in skeletally mature adolescents after the epi[INVESTIGATOR_883459], and all adolescent subjects enrolled into this study will have radiological confirmation of skeletal 
maturity.  No further long bone growth is anticipated after epi[INVESTIGATOR_883460]. 
 There are few treatment options for adolescents with mature skeletons and GCT of bone.  Based on the seriousness of GCT and the limited treatment options, [COMPANY_010] believes that this protocol, which includes adolescents with mature skeletons and GCT 
of bone, presents greater than minimal risk, but also presents the prospect of direct 
benefit to the subject 
Additional changes include the following: 
‚Ä¢ The sample size has been clarified to include approximately 100 subjects 
enrolled and the supporting sample size calculations  
‚Ä¢ An eligibility criteria excluding wome
n of child-bearing potential who are evidently 
pregnant or breast feeding has been added 
‚Ä¢ 
Extension of follow-up visit to up to 12 months from 6 months 
‚Ä¢ Other minor changes and typographical errors have been corrected throughout 
 
 
 
Confidential   
